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American Gastroenterological Association Institute Process for
Development of Technical Reviews
The aim of evidence-based medicine is to improve the quality of health care by integrating
the best research evidence with clinical expertise and patient values. Evidence-based clinical
guidelines are sets of recommendations intended to assist health care providers and patients
in selecting the best management for common clinical situations while accounting for
patient-specific circumstances. In addition to providing optimal, patient-centered care and
improved outcomes, guidelines can reduce practice variability, identify gaps in evidence,
enhance efficiency of resource use, and facilitate development of outcome and performance
measures.
The American Gastroenterological Association Institute (AGAI) Medical Position Statement
Procedure Manual, released in 2007, endorses the 2003 version of the US Preventive
Services Task Force system to grade strength of recommendations. Although an excellent
standard for producing recommendations regarding preventive services, the US Preventive
Services Task Force has limitations when used to assess interventions that are not based on
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prevention. The Grading of Recommendations Assessment, Development and Evaluation
(GRADE) system (http://www.gradeworkinggroup.org/index.htm) has been adopted by
several national and international societies and was constructed to address the shortcomings
of existing grading systems, including the US Preventive Services Task Force system.
GRADE separates quality of evidence from the strength of recommendation to ensure that
the magnitude of benefits and harms is assessed as rigorously as the efficacy of
interventions. With regard to strength of recommendations, GRADE has 2 categories: strong
and weak (Table 1). Strong recommendations are meant to signify interventions that should
be received by most individuals with a particular condition and can be adopted as policy in
most circumstances. Weak recommendations require individualized scrutiny of the evidence
and policy making would require substantial debate and involvement from multiple
stakeholders. The classification requires consideration of 4 factors: quality of evidence,
uncertainty about the balance between desirable and undesirable effects, variability in values
and preferences, and uncertainty about whether the intervention represents a wise use of
resources (Table 2). Of importance to our current health care debate is that interventions
receiving a strong recommendation may be targets for development of performance
measures.
Quality of evidence is assessed on a 4-point scale: high, moderate, low, and very low.
Instead of being classified strictly on the basis of study design (ie, randomized, controlled
clinical trials automatically receiving “high” quality marks), these levels reflect the
likelihood that further research would change our confidence in the estimate of the
beneficial effect of a particular intervention. Five factors that determine quality include
study limitations, inconsistency of results between studies, indirectness (generalizability) of
results, imprecision, and publication bias. For this reason, randomized, controlled clinical
trials that have methodological flaws may be downgraded, whereas well-done observational
studies that have large effect sizes (ie, relative risk [RR] >2–5 or <0.5–0.2) may be
upgraded.
AGAI Procedure for Construction of Technical Reviews
The AGAI Clinical Practice and Quality Management Committee (CPQMC) chooses a topic
by consensus discussion, votes after reviewing a list of potential topics derived from AGAI
member recommendations, and develops the specific questions the guideline will answer.
The CPQMC committee chair, with support of AGA staff, then contacts the AGAI clinical
counsel chair and requests the input of the counsel for authorship and external reviewers.
Authors are selected and write a technical review (TR), which is an evidence-based
document that provides the basis for clinical practice recommendations. For each of the
specific questions raised by the CPQMC, authors conduct an independent systematic review
of the literature using published guidelines (PRISMA). Articles selected for inclusion in the
TR are based on a priori inclusion and exclusion criteria agreed on by all authors. Data
extraction is shared among TR authors, and the individual study and summary results are
reviewed and approved by all authors. The search terms for each topic included in the TR
are included in the Appendix. It is not the function of the TR to provide a summary estimate
for each variable included in the review. For this reason, results are summarized in the text
of the TR and not subjected to a formal meta-analysis. The draft TR is compiled by the lead
author and approved by all authors before submission for publication.
A medical position panel composed of the TR authors, additional content experts, practicing
gastroenterologists, other specialists (eg, surgeon, pathologist), a patient representative, a
payer representative, and American Gastroenterological Association staff meet through a
series of face-to-face and telephone meetings to construct the medical position statement,
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which is based on the TR but also reflects these discussions by the medical position panel.
The medical position panel approves the medical position statement, after which this
document and the TR are reviewed by the CPQMC. Based on the vote of the committee, a
recommendation is submitted to the AGAI Governing Board, which provides final approval.
When approval is granted, the medical position statement is published in GASTROENTEROLOGY and
is also posted on the American Gastroenterological Association web site.
The objectives of the AGAI TR on the management of patients with Barrett's esophagus
were to evaluate diagnostic and management strategies for patients at risk for or diagnosed
with Barrett's esophagus. Specifically, 10 broad questions were developed by interaction
among the authors, the AGAI, the Clinical Practice and Quality Management Committee,
and representatives from the AGAI Council. The questions were designed to encapsulate the
major management issues leading to consultations for Barrett's esophagus and esophageal
adenocarcinoma in clinical practice in 2010. For each question, a comprehensive literature
search was conducted, pertinent evidence reviewed, and a summary of relevant data
produced. The conclusions of this review were based on the best available evidence or, in
the absence of quality evidence, the expert opinion of the authors of the TR.
What Is the Definition of Barrett's Esophagus? What Landmark Identifies the
Gastroesophageal Junction? What Epithelial Type Is Required for the Diagnosis of
Barrett's Esophagus? Should Endoscopists Measure the Extent of Barrett's Metaplasia?
Authorities generally have defined Barrett's esophagus conceptually as the condition in
which metaplastic columnar epithelium replaces the stratified squamous epithelium that
normally lines the distal esophagus.1–4 Unfortunately, this deceptively simple conceptual
definition does not translate readily into clinically useful diagnostic criteria for 2 major
reasons. (1) There are no universally accepted, precise, and validated landmarks that delimit
the distal extent of the esophagus (ie, that identify the gastroesophageal junction [GEJ]). If it
cannot be determined precisely where the esophagus ends and the stomach begins, then it
may not be possible to ascertain the type of epithelium that lines the most distal esophagus.
(2) There is no way to verify that gastric-type columnar epithelia found in the distal
esophagus are metaplastic. These 2 factors become major confounders when attempting to
establish a diagnosis of Barrett's esophagus for patients with only short segments of
esophageal columnar epithelium.
What Landmark Identifies the Gastroesophageal Junction?—The diagnosis of
Barrett's esophagus can be suspected when, during endoscopic examination, columnar
epithelium (which has a characteristic endoscopic appearance) is observed to extend above
the GEJ into the esophagus. Of course, this diagnostic suspicion is based on the assumption
that the endoscopist can identify the GEJ. Few studies have addressed specifically the issue
of how to localize the GEJ, and even those that have the accuracy of the criteria used cannot
be assessed meaningfully in the absence of a validated landmark (ie, a gold standard).
Western endoscopists generally identify the GEJ as the most proximal extent of the gastric
folds, a landmark first proposed in 1987 in a report of a small and methodologically flawed
study.5 The location of the proximal extent of the gastric folds is affected by respiration, gut
motor activity, and the degree of distention of the esophagus and stomach, all of which can
change from moment to moment. Endoscopists in Asia often use the distal extent of the
palisade vessels, which are fine longitudinal veins located in the lamina propria of the distal
esophagus, as their landmark for the GEJ.6,7 The palisade vessels can be obscured by
esophagitis, their level of termination can be irregular and difficult to localize with
precision, and conceptually it is not clear why the distal end of the palisade vessels should
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be considered the end of the esophagus. Thus, the scientific validity of the 2 most widely
used landmarks for the GEJ is dubious.
The issue of the “best” landmark for the GEJ is likely to remain controversial indefinitely
because, ultimately, the choice of any such landmark will be arbitrary. The majority of
published studies on Barrett's esophagus conducted over the past 20 years have used the
proximal extent of the gastric folds as the landmark for the GEJ and, in the absence of
compelling data for the use of alternative markers, we presently recommend the continued
use of this landmark despite its shortcomings.
What Epithelial Type Is Required for a Diagnosis of Barrett's Esophagus?—
Barrett's esophagus is judged to develop through the process of metaplasia in which one
adult cell type replaces another. For reasons that are not clear, Barrett's metaplasia is
predisposed to cancer development. Three types of columnar epithelia have been described
in Barrett's esophagus: (1) a gastric fundic-type epithelium that has mucus-secreting cells,
parietal cells, and chief cells; (2) a cardia-type (also known as junctional-type) epithelium
composed almost exclusively of mucus-secreting cells; and (3) an intestinal-type epithelium
(sometimes called specialized columnar epithelium or specialized intestinal metaplasia) that
contains prominent goblet cells.8 The fundic- and cardia-type epithelia in Barrett's
esophagus can be morphologically indistinguishable from columnar epithelia found in the
stomach.
If biopsy specimens of suspected Barrett's esophagus reveal only fundic- and cardia-type
epithelia, then it can be difficult to establish that those epithelial types are metaplastic
because (1) biopsy sampling error can result in inadvertent biopsy of the stomach instead of
the esophagus, especially when only short segments of columnar epithelium appear to
extend above the GEJ, and (2) some authorities have argued that the normal distal esophagus
can have short segments of a gastric-type columnar lining.9 With no precise landmark for
the GEJ, it is difficult to support or refute that contention. If biopsy specimens of suspected
Barrett's esophagus reveal intestinal-type epithelium, in contrast, then there is little doubt
that the epithelium is abnormal and metaplastic. This finding does not obviate the issue of
biopsy sampling error, however, because intestinal metaplasia is common in the stomach
that is chronically infected with Helicobacter pylori.10
Intestinal-type epithelium can be readily identified by the pathologist and, unlike the gastric-
type epithelia, intestinal-type epithelium is clearly abnormal when located in the esophagus.
Furthermore, early reports suggested that the intestinal-type epithelium in Barrett's
esophagus was the one predisposed to malignancy. For those reasons, practical more than
scientific or conceptual, investigators and clinicians adopted the policy of requiring the
demonstration of intestinal metaplasia in esophageal biopsy specimens as a sine qua non for
the diagnosis of Barrett's esophagus. However, recent findings have challenged the validity
of that practice. There are data to suggest that cardia-type epithelium may not be normal, but
rather may be a metaplastic lining that develops as a consequence of chronic
gastroesophageal reflux disease (GERD).11
Histochemical and genetic studies of cardia-type epithelium have revealed molecular
abnormalities, similar to those found in specialized intestinal metaplasia, that may
predispose to cancer development.12,13 Recent clinical studies also suggest that cardia-type
epithelium has malignant potential. In one such study of 141 patients who underwent
endoscopic mucosal resection (EMR) for small esophageal adenocarcinomas, 71% had
cardia-type epithelium, not intestinal metaplasia, found adjacent to the cancer, and 57% had
no intestinal metaplasia whatsoever found in the EMR specimen.14
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The columnar-lined esophagus has clinical importance only because it predisposes to the
development of esophageal cancer. The debate about whether patients who have only cardia-
type epithelium lining the distal esophagus have “Barrett's esophagus” is primarily a
semantic issue. The key unanswered clinical question for those patients is this: What is the
risk of developing esophageal cancer? The great majority of studies on the risk of cancer in
Barrett's esophagus have included patients with specialized intestinal metaplasia either
primarily or exclusively.15 Although recent data suggest that cardia-type epithelium may
well predispose to malignancy, the magnitude of that risk is not yet clear. A reasonable
estimate of cancer risk is needed to make rational management decisions for patients with
Barrett's esophagus, and no such estimate is available for patients who have only cardia-type
epithelium in their columnar-lined esophagus.
Despite reasonable arguments supporting the concept that Barrett's esophagus might be
defined by the presence of cardia-type as well as by intestinal-type epithelium in the
esophagus, there are substantial practical reasons for not adopting this definition into clinical
practice at this time. The inclusion of patients with cardia-type epithelium under the rubric
of “Barrett's esophagus” would substantially increase the number of patients with that
disorder, which would substantially increase treatment costs. The benefits of surveillance
and treatment programs for Barrett's esophagus are debated, even for patients with intestinal
metaplasia, whose cancer risk is far better defined. The likelihood of finding intestinal-type
epithelium in Barrett's esophagus varies directly with the extent of the esophageal columnar
lining, and the issue of whether to consider cardia-type epithelium a marker for Barrett's
esophagus usually concerns only patients with short segments of esophageal columnar
epithelium (generally segments considerably less than 3 cm in extent). The clinical benefit
of biopsy sampling for patients with such short segments of esophageal columnar epithelium
has not been established.
What Is the Definition of Barrett's Esophagus?—Any definition of Barrett's
esophagus necessarily will have an arbitrary component. If Barrett's esophagus is to be
considered a medical condition rather than merely an anatomic curiosity, then it should have
clinical importance. The columnar-lined esophagus has clinical importance only if it
predisposes to esophageal cancer. Therefore, we believe that Barrett's esophagus can be
defined conceptually as the condition in which any extent of metaplastic columnar
epithelium that predisposes to cancer development replaces the stratified squamous
epithelium that normally lines the distal esophagus. Presently, intestinal metaplasia is the
only one of the 3 types of esophageal columnar epithelia described that clearly predisposes
to malignancy; therefore, we suggest that the term “Barrett's esophagus” presently should be
used only for patients who have intestinal metaplasia in the esophagus. Circumstantial
evidence suggests that cardia-type epithelium also may be predisposed to cancer
development, but presently that predisposition has not been established and there are
insufficient data to make meaningful recommendations regarding the management of
patients who have a columnar-lined esophagus with cardia-type epithelium alone. If future
studies establish a malignant predisposition for cardia-type epithelium, then those patients
also can be considered to have Barrett's esophagus by our proposed definition. For now,
however, only patients with intestinal-type columnar metaplasia in the esophagus are known
to have an increased cancer risk, and only those patients meet our criteria for the diagnosis
of Barrett's esophagus.
Should Endoscopists Measure the Extent of Barrett's Metaplasia?—Barrett's
esophagus has been categorized as long segment (when the metaplastic epithelium extends
at least 3 cm above the GEJ) or short segment (when there is <3 cm of metaplastic
epithelium lining the esophagus).16 Another more recently proposed system for categorizing
Barrett's esophagus, the Prague C and M criteria, identifies both the circumferential extent
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(C) and the maximum extent (M) of Barrett's metaplasia.17 One study has shown excellent
interobserver agreement among endoscopists using the Prague C and M criteria when
columnar epithelium extends at least 1 cm above the GEJ but poor agreement for shorter
segments of esophageal columnar lining.17
There may be clinical value in measuring the extent of Barrett's metaplasia visualized during
endoscopic examination (ie, the distance between the GEJ and the squamocolumnar junction
in the esophagus). Data suggest that the likelihood of finding intestinal metaplasia in the
columnar-lined esophagus and the magnitude of the cancer risk vary directly with the extent
of the metaplastic lining (see the following text). For patients found to have dysplasia in
Barrett's esophagus, furthermore, the extent of metaplasia is a factor that may influence the
choice among the therapeutic options (see the following text). Therefore, we advocate the
use of a system, like the Prague C and M criteria, that provides information on the extent of
Barrett's metaplasia. However, the clinical benefit of using any proposed endoscopic system
for classifying Barrett's esophagus has not been established by formal investigation and,
presently, patients with any extent of intestinal metaplasia are managed similarly.
What Is the Risk of Esophageal Cancer for the General Population of Patients With
Barrett's Esophagus?
A number of older reports linking Barrett's esophagus to esophageal adenocarcinoma
described an inordinately high incidence of cancer, in the range of 20 to 40 per 1000 person-
years (2%–4% per year).18–20 A variety of confounding factors, including selection bias, the
inclusion of prevalent cancers, and publication bias, may have contributed to the
overestimation of cancer risk in those studies.15 Subsequent reports of larger series generally
have described a substantially lower cancer risk for patients with Barrett's esophagus, but
even some modern reports describe very high cancer incidence rates.21 National health
statistics cannot be used to estimate cancer risk because the denominator (ie, the total
number of persons with Barrett's esophagus in the general population) is not known.
Nevertheless, a reasonable estimate of the incidence of cancer in Barrett's esophagus is
needed to formulate rational management strategies for patients with this condition.
A number of systematic reviews of studies on the incidence of cancer in patients with
Barrett's esophagus have been published.15,22–24 A recent review described outcomes for 47
studies that met inclusion criteria from an initial search that yielded 7780 publications from
MEDLINE and EMBASE databases (years 1950–2006).24 The overall estimate of cancer
incidence was based on 209 cancers discovered in 11,279 patients with Barrett's esophagus
who were followed up for 47,496 person-years. The average incidence of cancer was 6.1 per
1000 person-years, but this estimate may have been spuriously high because it included
patients in whom cancer was discovered within the first year after the diagnosis of Barrett's
esophagus. Such patients likely had prevalent cancers that were missed on their initial
endoscopic examinations. After adjusting the results to exclude those patients, the incidence
of cancer was 5.3 per 1000 person-years (0.5% per year), an estimate well aligned with the
results of prior systematic reviews.
Among 4 studies published since the aforementioned systematic review was a report of a
cohort of 502 patients with Barrett's esophagus from Leeds in the United Kingdom.25 The
annual incidence of cancer among patients who had Barrett's esophagus with specialized
intestinal metaplasia was 16 per 1000 person-years (1.6% per year). Another single-center
cohort from Birmingham in the United Kingdom calculated an incidence of 3.1 per 1000
person-years (0.3% per year) based on 3 cancers diagnosed among 188 patients with
Barrett's esophagus.26 A third study from the United Kingdom reported statistics from a
multicenter national registry involving 738 patients with a combined follow-up of 3697
years. The overall annual incidence of esophageal adenocarcinoma was 0.5% (95%
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confidence interval [CI], 0.3–0.8).27 Finally, an endoscopic and pathology-based database in
Spain was retrospectively examined to calculate a cancer risk in patients with Barrett's
esophagus of 5.2 per 1000 person-years (0.5% per year).28
The risk of cancer in Barrett's esophagus appears to vary with the extent of esophageal
metaplasia; therefore, patients with long-segment disease may have a higher incidence of
adenocarcinoma than those with short-segment Barrett's esophagus.23 In the aforementioned
Spanish cohort, for example, the annual risk of esophageal adenocarcinoma was 0.57% for
patients with long-segment Barrett's esophagus compared with only 0.26% for patients with
short-segment disease.28 The risk of cancer development also is lower in women than in
men with Barrett's esophagus (4.5 vs 10.2 cancers per 1000 person-years).24
The precise risk of cancer in Barrett's esophagus remains unclear. Reported estimates of
cancer risk continue to vary widely, and it is not clear how biases, statistical aberrations, and
regional differences in incidence rates contribute to the disparities among the published
reports. Methodologically, larger studies (ie, 500 or more person-years of observation)
report lower cancer incidence rates than smaller studies, as do studies that represent
population-based as opposed to referral-based cohorts.24 Estimates of cancer risk also are
likely to be affected by the proportion of patients with short-segment Barrett's esophagus
and women in the cohort. With these limitations in mind, most modern systematic reviews
and large series suggest that the annual incidence of cancer for the general population of
patients with Barrett's esophagus is approximately 0.5% per year. For patients with dysplasia
in Barrett's epithelium, the risk of cancer is substantially higher (see the following text).
Does Barrett's Esophagus Affect Life Expectancy? How Does a Diagnosis of Barrett's
Esophagus Affect Quality of Life?
Does Barrett's Esophagus Affect Life Expectancy?—A review of the literature
reveals some contradictory results for studies assessing the impact of a diagnosis of Barrett's
esophagus on life expectancy. In a population-based study in Northern Ireland, Anderson et
al compared mortality rates for subjects with Barrett's esophagus with those for age- and
sex-matched subjects in the general population. The investigators found no significant
differences in overall mortality rates between the 2 groups.29 Although deaths from
esophageal cancer were more common in the group with Barrett's esophagus, the total
frequency of such deaths was so low that it had little effect on overall mortality. Another
study that compared survival for subjects with Barrett's esophagus with survival for 2
control groups (the general population and patients with Schatzki's rings) also found no
difference in life expectancy among the groups.30 In contrast, Moayyedi et al in the United
Kingdom found increased mortality for subjects who had Barrett's esophagus diagnosed at 4
hospitals in Leicestershire compared with age- and sex-matched subjects in the general
population.31 Interestingly, however, the excess mortality in the patients with Barrett's
esophagus was primarily due to extraesophageal diseases such as bronchopneumonia and
ischemic heart disease. In another large population-based study in which survival for a
cohort of 1677 patients with Barrett's esophagus was compared with an age- and sex-
matched cohort of 13,416 individuals in the general population, Solaymani-Dodaran et al
found that the patients with Barrett's esophagus had a 37% increase in mortality.32
Approximately 45% of the excess mortality in the patients with Barrett's esophagus was due
to esophageal cancer, whereas 55% was due to extraesophageal disorders such as
cardiovascular disease. The excess deaths from cardiovascular problems may be related to
the association of Barrett's esophagus with obesity, which also is a risk factor for
cardiovascular disease.
Despite the somewhat disparate findings of these studies on survival for patients with
Barrett's esophagus, several conclusions are warranted. First, even though deaths from
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esophageal adenocarcinoma are more common in patients with Barrett's esophagus than in
individuals without that condition, adenocarcinoma remains an uncommon cause of
mortality in patients with Barrett's esophagus nevertheless.33,34 Furthermore, because this
cancer generally occurs later in life,35 the impact of such a death on the mean survival of the
cohort is lessened, because deaths due to extraesophageal diseases such as cardiovascular
disorders are far more common and therefore drive overall mortality rates. It also appears
that mortality due to cardiovascular disease may be increased in patients with Barrett's
esophagus, perhaps because of the association of the disorder with obesity.
How Does a Diagnosis of Barrett's Esophagus Affect Quality of Life?—
Numerous studies have attempted to quantify the quality of life in patients with Barrett's
esophagus, but those studies are limited in several important ways. First, they lump all
subjects with prevalent disease into a single category and compare that group with controls
such as subjects who have GERD without Barrett's esophagus or the general population. It is
likely that the quality of life for patients with Barrett's esophagus varies with a number of
important factors, such as disease duration and the number of surveillance endoscopies
performed, that are not accounted for in such studies. Second, the studies generally use a
convenience sample of subjects with Barrett's esophagus attending outpatient clinics or
endoscopy units at tertiary care centers. The impact of the disease on such subjects may be
very different from that on the general population of individuals with Barrett's esophagus.
For instance, one might expect subjects attending repeated endoscopic surveillance sessions
to be more concerned about their risk of developing adenocarcinoma than those who forego
such measures. Finally, there is no validated, disease-specific, widely accepted quality-of-
life measure for Barrett's esophagus. Investigators have used generic quality-of-life
measures as well as organ-specific measures and tools developed specifically for GERD
populations. Those tools may fail to capture important domains of quality of life for subjects
with Barrett's esophagus.
With these limitations in mind, a systematic review found 25 articles in the English-
language literature that provide quantitative assessments of quality of life or financial and
psychological burdens of disease for subjects with Barrett's esophagus.36 Five studies
assessed patients using the generic quality-of-life measure 36-Item Short Form Health
Survey (SF-36),37 3 studies used Quality of Life in Reflux and Dyspepsia (QOLRAD),38
and 2 studies used Gastrointestinal Quality of Life Index.39 Four studies evaluated utility
measures in patients with Barrett's esophagus. Utilities rate the desirability of living with a
given disease state on a scale of 0 to 1, where a rating of 1 indicates essentially no decrease
in the desirability of life and 0 indicates a quality of life so undesirable it is equal to death.
Eight studies did not use traditional quality-of-life instruments but quantitatively assessed
impact (psychological, financial, social, and so on) or burden of disease by other measures.
Of these 25 studies, 9 included patients with Barrett's esophagus as a subset of patients with
GERD symptoms or a priori compared patients with Barrett's esophagus with patients with
GERD. The remaining 16 studies included only patients with Barrett's esophagus.
On balance, these studies show that a diagnosis of Barrett's esophagus has a substantial
negative impact on quality of life. All reported cohorts showed lower SF-36 scores in
subjects with Barrett's esophagus compared with the population norms. Studies using organ-
specific measures such as QOLRAD and Gastrointestinal Quality of Life Index also showed
diminished quality of life in subjects with Barrett's esophagus compared with the population
norms. One study found similar QOLRAD scores in patients with Barrett's esophagus and
patients with GERD. Whereas both groups reported substantial GERD symptoms, it is
possible that a major component of the decrease in quality of life experienced by the patients
with Barrett's esophagus was due to their GERD symptoms. Attempts to quantify quality of
life in Barrett's esophagus using health state utilities have repeatedly shown diminished
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utility for life with this condition. The negative impact on utility varies with the degree of
dysplasia in Barrett's epithelium and has been reported to be as low as 0.77 for patients with
high-grade dysplasia.40
Although subjects with Barrett's esophagus are consistently found to have a poorer quality of
life than the general population, it is unclear to what extent this is attributable to anxiety
regarding cancer risk, discomfort due to GERD symptoms, or other factors. Patients with
Barrett's esophagus appear to greatly overestimate their cancer risk, and this overestimation
is associated with an increase in their utilization of health care.41 In addition to this
psychological distress, patients with Barrett's esophagus face higher individual costs for life
insurance and may be unable to obtain health insurance.42
In summary, by generic and organ-specific quality-of-life measures, subjects with Barrett's
esophagus repeatedly have been shown to have substantially lower scores than population
norms. Subjects with Barrett's esophagus consistently report their utility of living with the
disease lower than without it, and the decrease in utility correlates with the degree of
dysplasia in Barrett's epithelium. A diagnosis of Barrett's esophagus appears to cause
psychological stress and may be associated with substantial, but incompletely understood,
additional costs such as increased life and health insurance premiums.
Who Is at Risk for Barrett's Esophagus? Who Should Be Screened for Barrett's
Esophagus?
Who Is at Risk for Barrett's Esophagus?—A systematic review of original literature
on the epidemiology of Barrett's esophagus shows that most published studies describe
hospital-based or endoscopy clinic–based cohorts; relatively few describe large population-
based cohorts. It is important to consider this potential bias when assessing those
epidemiologic studies, which have identified a number of risk factors for Barrett's
esophagus. Selected risk factors are reviewed briefly in the following text.
It is not clear when Barrett's esophagus develops, but most recognized cases are diagnosed
in the sixth decade of life or later.43,44 Although the utilization of endoscopy (and hence the
chance of finding Barrett's esophagus) is higher in older subjects, cohort studies suggest that,
as age increases, so does the likelihood that a subject with GERD symptoms will have
Barrett's esophagus.43 Whether the condition results from a single catastrophic insult to the
esophageal mucosa, which may be more likely to occur in older subjects, or whether
Barrett's esophagus is the cumulative result of years of reflux-induced damage is not clear.
Longitudinal studies, which have found that the extent of Barrett's metaplasia does not
increase with time (at least in subjects on therapy), provide some support for the concept
that the condition develops all at once.45
There is a male predominance for Barrett's esophagus, as there is for esophageal
adenocarcinoma. In case-control and cohort studies, the risk of Barrett's esophagus among
men with GERD symptoms is 1.5- to 3-fold higher than that of women.44,46–48 A recent
meta-analysis of cohort studies comprising consecutively enrolled subjects with Barrett's
esophagus shows a case mix of men and women of approximately 2:1.49 Whether this male
preponderance is the result of differences between men and women in hormonal effects on
the esophagus, body fat distribution, or other as-yet unidentified factors is not clear.
Most cohort studies show that the majority of subjects with Barrett's esophagus are white.48
Because most of these studies are clinic or hospital based, some of the apparent ethnic
predisposition may be biased by the underlying demographics of the patients who attend
those facilities. Several studies have attempted to quantify how the proportion of subjects
with heartburn who have Barrett's esophagus varies among different ethnic groups. Abrams
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et al found that, among subjects who underwent endoscopy at their institution, white
subjects were approximately 4 times as likely to have Barrett's esophagus as Hispanic or
black subjects.43 Similarly, a cohort study of subjects presenting for screening colonoscopy
who were invited to undergo upper endoscopy found that white subjects were more likely to
have Barrett's esophagus than black subjects.50 In a community-based study, Corley et al
found that the incidence of Barrett's esophagus in non-Hispanic white subjects was more
than 6 times greater than that in black subjects.48 In contrast, Eloubeidi et al did not find
race to be a predictor of Barrett's esophagus in a Veterans Administration population.51 If
there are significant differences in the prevalence of Barrett's esophagus between white and
black subjects, they are not likely the result of differences in the underlying prevalence of
GERD, because the distribution of heartburn symptoms appears to be similar between those
2 groups.52 However, limited studies suggest that both GERD and Barrett's esophagus are
far less common in Asian patients than in white subjects.53
GERD is strongly associated with Barrett's esophagus. Case-control studies suggest that
subjects with heartburn are 6 to 10 times more likely to have Barrett's esophagus than those
without heartburn. Furthermore, there appears to be a dose-response relationship in that
subjects with more frequent or chronic GERD symptoms are more likely to have Barrett's
esophagus.51,54–57 Hiatal hernia also is associated with the presence of Barrett's
esophagus.46,55 However, the relationship between GERD symptom severity and Barrett's
esophagus is not as strong.51
Cohort and case-control studies assessing esophageal acid exposure in subjects who have
GERD with and without Barrett's esophagus showed that those with Barrett's esophagus
have, on average, greater acid exposure than those without and that the extent of Barrett's
metaplasia correlates directly with the duration of esophageal acid exposure.55 Increased
bile reflux (as estimated by a system that measures esophageal exposure to bilirubin) also
has been documented in subjects with Barrett's esophagus,46,58 but the role of components
of refluxate other than acid in the development of the condition remains controversial.
A high body mass index and an intra-abdominal distribution of body fat have been shown to
be strong risk factors for Barrett's esophagus. Patients with Barrett's esophagus have, on
average, a higher body mass index than either patients with GERD without Barrett's
esophagus or general population controls.59–61 Interestingly, the distribution of body fat may
be the key to this association. For any given body mass index, subjects with higher amounts
of intra-abdominal obesity, manifest either radiographically or by increased waist-to-hip
ratio measures, appear to have an increased risk of Barrett's esophagus.59,60,62 In fact, in a
recent analysis of body anthropometry in subjects with Barrett's esophagus, body mass index
was no longer an independent predictor of the disorder once waist-to-hip ratio was
factored.62 Whether the increased risk associated with intra-abdominal obesity is due to
mechanical or hormonal factors or a consequence of yet-undescribed factors is not known.
Alcohol and smoking are not nearly as strongly associated with Barrett's esophagus as they
are with squamous cell cancer of the esophagus, and studies on the association of these
habits with Barrett's esophagus have yielded inconsistent results. In a population-based
study, Ronkainen et al showed that subjects who used tobacco or alcohol were
approximately 3 times as likely to have Barrett's esophagus as subjects who did not.63 Other
studies have found an association between either smoking44 or alcohol64 and Barrett's
esophagus, whereas a number of investigations have not.65–67 In fact, recent data suggest
that consumption of wine actually may protect against Barrett's esophagus.65,66 High
vegetable and fruit intake appear to diminish the risk of Barrett's esophagus, although the
mechanism is not known.68,69
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In summary, well-established risk factors for Barrett's esophagus include advanced age,
male sex, white ethnicity, GERD, hiatal hernia, elevated body mass index, and a
predominantly intra-abdominal distribution of body fat. Moderate consumption of wine and
a diet high in fruits and vegetables may protect against the disorder.
Who Should Be Screened for Barrett's Esophagus?—Despite the considerable
published data available on risk factors for Barrett's esophagus, few attempts have been
made to apply this information systematically in the design of guidelines on who to screen
for the condition. Furthermore, despite the dearth of studies showing clinical benefit
resulting from endoscopic screening for Barrett's esophagus, the practice remains
widespread among clinicians in the United States.70 Professional organizations are divided
on whether to recommend endoscopic screening for Barrett's esophagus, however, with
some suggesting that the practice may be appropriate71 and others not endorsing it
routinely.72,73
Most recommendations on screening for Barrett's esophagus have focused on subjects with
chronic GERD symptoms, because GERD was one of the first and strongest risk factors for
Barrett's esophagus identified and because chronic esophageal inflammation due to GERD
has been thought to contribute to esophageal carcinogenesis. Several cohort and case-control
studies suggest that endoscopic screening and surveillance for Barrett's esophagus can have
beneficial effects.74,75 Subjects who have esophageal adenocarcinoma discovered as the
result of an endoscopic screening or surveillance program for Barrett's esophagus present
with earlier-stage tumors, are less likely to have lymph node involvement, and have better
short-term life expectancies than patients who present with symptoms of esophageal cancer
such as dysphagia and weight loss. Cost-effectiveness analyses suggest that endoscopic
screening may be cost-effective if certain predefined clinical parameters are met.76,77
Although these data may seem compelling, several conceptual and logistical difficulties
diminish the utility of screening endoscopy as it is currently practiced in the United States.
First and foremost, approximately 40% of subjects who have adenocarcinoma of the
esophagus report no history of chronic GERD symptoms.78 Using GERD symptoms as an
entrance criterion to endoscopic screening programs immediately excludes those subjects,
decreasing by almost one-half our ability either to prevent the cancer or to detect it at an
early, presymptomatic stage. Second, even among subjects with GERD symptoms, the risk
of adenocarcinoma is very low in absolute terms. Studies show that up to 40% of the adult
US population experience GERD symptoms on a monthly basis and 20% on a weekly
basis.79 Although the incidence of adenocarcinoma of the esophagus has increased 6-fold in
the past 3 decades,80 fewer than 10,000 Americans develop esophageal adenocarcinoma
each year, representing a minute fraction of the total number of individuals with GERD
symptoms. Even among patients with Barrett's esophagus, cohort studies show that more
than 90% never develop esophageal adenocarcinoma.81 Therefore, the vast majority of
individuals who undergo endoscopic screening for Barrett's esophagus based on the presence
of GERD symptoms will not benefit from the procedure.
There also are substantial problems with the execution of various facets of endoscopic
screening and surveillance programs that diminish their effectiveness. These include
difficulties in the endoscopic recognition of important lesions,82 the random nature of
esophageal biopsy sampling that is subject to considerable sampling error,83 and
disagreement among pathologists in the histologic interpretation of the esophageal biopsy
specimens.84 Finally, endoscopic examinations are expensive, especially after factoring in
costs not only for the endoscopy but also for the tissue acquisition and interpretation.
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No direct evidence substantiates the utility of endoscopic screening for Barrett's esophagus,
and substantial confounding factors such as lead time and length bias compromise the
validity of the observational studies, suggesting that the practice is beneficial.85 Therefore,
inadequate evidence exists to endorse endoscopic screening for Barrett's esophagus based
solely on the presence of GERD symptoms, and decisions on when to recommend
endoscopic screening should continue to be individualized. It is incumbent on the
practitioner to ensure that patients who elect to undergo endoscopic screening for Barrett's
esophagus understand not only the putative advantages of the procedure but also the
substantial shortcomings and possible negative effects, which include the expense and risks
of the endoscopy and of the invasive procedures that might be recommended to treat lesions
found by endoscopy as well as the potential adverse impact on quality of life (see the
following text). Whether the development of new endoscopic technologies that are more
sensitive, less expensive, and easier to perform or the availability of improved endoscopic
treatments for Barrett's esophagus eventually will tip the scales in favor of screening is not
yet known.
What Is the Natural History of Dysplasia in Barrett's Esophagus?
During the process of carcinogenesis in Barrett's esophagus, some of the genetic alterations
that endow cells with growth advantages (eg, activation of oncogenes, inactivation of tumor
suppressor genes) also cause morphologic changes in the tissue that the pathologist
recognizes as dysplasia (also called intraepithelial neoplasia). Thus, dysplasia can be viewed
as the histologic expression of genetic alterations that favor unregulated cell growth.86
Dysplasia can be categorized as low grade or high grade depending on the degree of
histologic abnormalities. Pathologists can have difficulty distinguishing low-grade dysplasia
in Barrett's esophagus from reactive changes caused by reflux esophagitis; consequently,
interobserver agreement for the diagnosis of low-grade dysplasia may be poor.
Dysplasia in Barrett's esophagus sometimes causes no endoscopically apparent
abnormalities, and dysplasia can be patchy both in its extent and severity. These factors
contribute to the substantial problem of biopsy sampling error in identifying dysplasia.
Endoscopists traditionally have used a 4-quadrant biopsy sampling system (which is
essentially a random sampling technique) to find dysplasia in Barrett's esophagus, and it is
clear that this system can miss areas of dysplasia and even cancer. In series of patients who
underwent esophagectomies because endoscopic examination revealed high-grade dysplasia
in Barrett's esophagus, for example, a number of studies have found that invasive cancer is
present in 30% to 40% of the resected esophagi.87 However, a recent critical review of those
studies suggests that 13% is a more accurate estimate of the frequency of invasive cancer in
this situation, and when a careful endoscopic examination excludes all visible lesions, the
frequency of finding invasive cancer at esophagectomy is only 3%.88
A meta-analysis published in 2008 focused on the incidence of esophageal adenocarcinoma
in patients with high-grade dysplasia in Barrett's esophagus.89 The literature search of
MEDLINE and associated sources yielded 3843 citations, of which 196 were deemed
potentially relevant; on complete review, however, only 4 articles met the inclusion criteria
for the study (ie, study patients had histologically confirmed Barrett's esophagus with high-
grade dysplasia, no prevalent cancer, and no ablative or surgical therapy). The crude
incidence of esophageal adenocarcinoma among patients with high-grade dysplasia was 55.7
per 1000 person-years (5.6% per year). Using different weighting algorithms, the incidence
increased to 65.8 per 1000 person-years (6.6% per year) with 95% CIs of 49.9 to 84.6
(Poisson) or 49.7 to 81.8 (binomial) per 1000 person-years of observation.
The incidence of cancer in patients who have low-grade dysplasia in Barrett's esophagus is
especially poorly defined. Some studies have found a risk of cancer no greater than that for
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the entire population of patients with Barrett's esophagus,90–92 whereas others have
observed considerably higher rates.84,93 One reason for these disparities may be the poor
interobserver correlation among pathologists in the diagnosis of low-grade dysplasia.94 This
possibility is supported by the observation that, among patients whose diagnosis of low-
grade dysplasia is confirmed by 2 or more pathologists, the incidence of cancer is
substantially higher than that for patients whose pathologists disagree on the diagnosis.84,93
The “extent” of low-grade dysplasia defined as the proportion of crypts that exhibit
dysplastic changes has been suggested to improve the ability to discern which patients are at
greater risk for development of cancer.95
Another unresolved issue is whether dysplasia can regress or whether the inability to
demonstrate dysplasia on follow-up endoscopic examinations is merely the result of biopsy
sampling error. In one of the largest multicenter longitudinal studies, 42% of patients
initially diagnosed with low-grade dysplasia had no dysplasia found on subsequent
endoscopic examinations and an additional 32% had low-grade dysplasia found only
intermittently during their course of surveillance.92 In this study, the calculated incidence of
esophageal adenocarcinoma among patients with low-grade dysplasia was 0.6% per year
(95% CI, 0–2%), a rate of cancer development similar to that reported for the general
population of patients with Barrett's esophagus. On the other hand, 3 patients in whom
cancer developed did not have dysplasia diagnosed during prior endoscopic surveillance
examinations. It is not clear whether those cancers developed de novo, without first
manifesting dysplasia, or whether the preceding dysplasia merely was missed due to biopsy
sampling error. Other reports also have described the apparent regression of dysplasia in the
absence of ablation.22
Does Endoscopic Surveillance Improve Survival for Patients With Barrett's Esophagus?
Endoscopic surveillance has been proposed for patients with Barrett's esophagus with the
unproved assumption that the practice will reduce deaths from esophageal adenocarcinoma
and thereby prolong survival. Societal guidelines generally have recommended endoscopic
surveillance for patients with Barrett's esophagus at intervals that vary with grade of
dysplasia found in the metaplastic epithelium. Intervals of 3 to 5 years have been suggested
for patients who have no dysplasia, 6 to 12 months for those found to have low-grade
dysplasia, and every 3 months for patients with high-grade dysplasia who receive no
invasive therapy.72
During endoscopic surveillance, the endoscopist attempts to identify esophageal neoplasia in
an early, curable stage, usually in the form of dysplasia. To find dysplasia, endoscopists
generally have relied on a systematic, 4-quadrant biopsy sampling technique designed with
the intent of maximizing the chance for identifying an inconspicuous lesion that may be
randomly distributed throughout the Barrett's epithelium. The “Seattle protocol” calls for
obtaining such 4-quadrant biopsy specimens at intervals of every 1 to 2 cm throughout the
columnar-lined esophagus. In addition, areas of mucosal irregularity (eg, nodules, masses,
ulceration), which are especially likely to be associated with dysplasia, are sampled
separately.
A prospective study showed a significant increase in the number of cases of high-grade
dysplasia and invasive cancer detected after institution of a rigorous endoscopic surveillance
protocol like the one described previously.96 In the community, however, surveillance often
is not performed in this rigorous manner. A retrospective study of endoscopic and pathology
reports from 15 hospitals in The Netherlands revealed that adherence to the Seattle protocol
was good (79%) for cases in which Barrett's metaplasia involved only up to 5 cm of the
distal esophagus but diminished with increasing extent of metaplasia to the point that there
was only 30% adherence among cases with metaplasia involving 10 to 15 cm of the
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esophagus.97 An American study using a large pathology database maintained by Caris
Diagnostics identified 2245 patients who had esophageal biopsy specimens taken for
evaluation of Barrett's esophagus and who had endoscopy reports that documented the
extent of esophageal columnar lining.98 Overall, adherence to the Seattle protocol was found
in only 51% of cases. As in the previous study, adherence to the protocol varied inversely
with the extent of Barrett's metaplasia. In addition, failure to adhere to the protocol was
associated with a significantly decreased rate of detecting dysplasia (summary odds ratio,
0.53; 95% CI, 0.35–0.82). These studies suggest that, although adherence to recommended
surveillance procedures is associated with higher rates of detection of dysplasia, many
practicing gastroenterologists do not adhere to those guidelines and adherence appears to be
poorest for the population at highest risk for development of cancer (ie, patients with
extensive Barrett's metaplasia).
Streitz et al studied 77 patients who they treated for esophageal adenocarcinoma to explore
whether prior endoscopic surveillance was associated with better survival (Table 3).99 In 19
patients, the cancers were found during surveillance endoscopies performed because
Barrett's esophagus had been discovered 8 to 120 months earlier (median, 24 months). The
remaining 58 patients presented to the hospital with symptoms of esophageal cancer, and
Barrett's esophagus was first diagnosed when their tumors were resected. Compared with the
latter patients, the patients whose tumors were discovered during endoscopic surveillance
had cancers in significantly lower stages and had a significantly better 5-year actuarial
survival rate (62% vs 20%). It should be noted that 9 patients in the surveillance group had
esophagectomy performed for carcinoma in situ or high-grade dysplasia, although 2 of these
had invasive carcinoma found in the resected specimen.
Peters et al reported the results of a similar study comparing outcomes for 17 patients who
had esophagectomy performed for high-grade dysplasia or adenocarcinoma discovered
during endoscopic surveillance with those for 35 patients who had esophagectomy for
adenocarcinomas discovered outside a surveillance program.100 Although the endoscopic
surveillance protocol was not standardized, all 17 patients had a diagnosis of Barrett's
esophagus without cancer established at least 6 months before esophagectomy. Five of the 9
patients who underwent resection for high-grade dysplasia were found to have invasive
cancer in the resected specimen. As in the previous study, the patients whose tumors were
discovered during surveillance had cancers in significantly lower stages and longer
survivals.
In another single-center experience, Van Sandick et al also compared outcomes for patients
with adenocarcinoma of the esophagus or esophagogastric junction discovered in and
outside endoscopic surveillance programs.75 The 16 patients in the surveillance group were
known to have had Barrett's esophagus for a median duration of 42 months, and they had
been under endoscopic surveillance for intervals ranging from 2 months to 2.5 years
(median, 10 months). Five of those 16 patients had esophagectomy for high-grade dysplasia;
1 was found to have invasive cancer, 2 were found to have intramucosal carcinoma, and 2
had only high-grade dysplasia found in the resected esophagus. Compared with the 54
patients whose tumors were discovered outside a surveillance program, the pathologic stage
of cancer was significantly lower for patients in the surveillance group, and their 2-year
survival was significantly better (85.9% vs 43.3%; P = .0029). Surveillance was associated
with significantly longer survival even when patients with a preoperative diagnosis of high-
grade dysplasia (without cancer) were excluded from the analysis.
Fountoulakis et al studied a cohort of consecutive patients who underwent esophagectomy
for high-grade dysplasia or adenocarcinoma in Barrett's esophagus, comparing the survival
of those whose neoplasms were discovered in and outside a standardized endoscopic
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surveillance program.101 The surveillance group included 17 patients who had at least one
endoscopy performed at least 6 months after their first diagnosis of Barrett's esophagus,
whereas the no-surveillance group comprised 74 patients who first presented to the hospital
with adenocarcinoma. Overall survival was significantly longer for patients in the
surveillance group, with 1- and 3- year survival rates for the surveillance and no-
surveillance groups of 88% versus 67% and 80% versus 31%, respectively.
Using the Northern California Kaiser Permanente cancer registry, Corley et al studied
outcomes for 589 patients with adenocarcinoma of the esophagus or gastric cardia diagnosed
from 1990 to 1998.74 Among only 23 patients who were known to have had Barrett's
esophagus for at least 6 months before the cancer was diagnosed, 15 had their tumors
discovered during surveillance endoscopy, whereas 8 had their cancers detected during
endoscopy performed because of cancer symptoms. As in the single-center observational
studies discussed previously, the patients whose tumors were discovered during surveillance
had cancers at significantly lower stages and had significantly better 2-year survival
compared with the patients whose tumors were discovered because they were symptomatic
(73.3% vs 12.5%; P = .02).
Cooper et al studied a cohort of 1633 patients in the Surveillance, Epidemiology and End
Results (SEER) database who had adenocarcinoma of the esophagus or gastric cardia.102
Through linkage with Medicare claims data, the investigators were able to identify those
who had endoscopy performed more than 1 year before the cancer was diagnosed. A record
of prior endoscopy was found in only 9.7% of the patients, and only 3.7% had Barrett's
esophagus identified at least 1 year before the diagnosis of cancer. However, a prior
diagnosis of Barrett's esophagus was associated with a lower cancer stage and a higher
probability of treatment by esophagectomy. The median survival for patients with
esophageal adenocarcinoma who had a prior endoscopy was 7 months, compared with only
5 months for those who had no prior endoscopy (P < .01). The association between prior
endoscopy and prolonged survival remained significant even after adjusting for age at
diagnosis, sex, race, and number of comorbidities using Cox proportional hazards modeling
(relative hazards, 0.73; 95% CI, 0.57–0.93).
A more recent analysis of the SEER-Medicare data conducted by Cooper et al included 2754
patients with a new diagnosis of esophageal adenocarcinoma.103 Having an endoscopy
performed 3 years to 6 months before the diagnosis of cancer was associated with an
improvement in median survival from 7 months (for patients with no prior endoscopy) to 11
months, yielding a significant reduction in the hazard ratio for death. Additional independent
factors associated with improved survival included a prior diagnosis of Barrett's esophagus
and receipt of therapy, including surgery, radiation, or chemotherapy. Of note, however,
only 11.5% of the patients with cancer were found to have had a prior endoscopy, and
Barrett's esophagus was identified in only 8.1% of patients before their diagnosis of cancer.
In a case-control study using the Veterans Affairs database, Kearney et al found that a group
of 245 patients who had GERD and adenocarcinoma of the esophagus or gastric cardia were
significantly less likely to have undergone endoscopy in the 1 to 8 years before the index
date than 980 control subjects (matched by age, sex, and race) who had GERD without
cancer (adjusted odds ratio, 0.66; 95% CI, 0.45–0.96).104 Furthermore, a dose effect was
noted whereby endoscopy performed 2 to 4 years before the index date was more protective
against cancer death than endoscopy performed more than 4 years before that date.
Countering these positive results is a retrospective, controlled, cohort study by Rubenstein et
al that used the Veterans Affairs national administrative databases to identify 155 subjects
who had GERD associated with adenocarcinoma of the esophagus or esophagogastric
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junction.105 Although the 25 patients who had endoscopy performed 1 to 5 years before
their diagnosis of cancer had tumors in a lower stage than the 130 patients who had no
endoscopy during that same period, there was no significant difference in survival between
the 2 groups (adjusted hazard ratio, 0.93; 95% CI, 0.58–1.50). Analysis of a subset of
subjects for whom complete endoscopic and histopathologic data were available revealed
that patients who had endoscopic surveillance performed according to guidelines proposed
by the American College of Gastroenterology had better survival than those who did not.
After adjustment for potential confounders, however, the improvement in survival did not
achieve statistical significance. This study highlights the potential for lead- and length-time
biases that can exaggerate the benefits of surveillance programs in observational studies.
In summary, the evidence to support endoscopic surveillance as a means to improve survival
for patients who develop neoplasia in Barrett's esophagus relies on administrative data that
have been examined retrospectively. The preponderance of this evidence suggests that
endoscopic surveillance can reduce mortality from esophageal adenocarcinoma through the
early detection of treatable cancers. However, such observational studies are prone to a
number of biases, such as lead- and length-time biases, that could well exaggerate the
benefits of surveillance programs. It remains unclear whether endoscopic surveillance is
beneficial at all; consequently, it is not possible to make meaningful recommendations
regarding the optimal intervals between endoscopic procedures or the optimal surveillance
biopsy procedures.
Can Biomarkers Be Used to Confirm the Histologic Diagnosis of Dysplasia? Can
Biomarkers Be Used Instead of Dysplasia for Risk Stratification in Barrett's Esophagus?
Can Biomarkers Be Used to Confirm the Histologic Diagnosis of Dysplasia?—
Presently, cancer risk stratification for patients with Barrett's esophagus is based primarily
on the histologic finding of dysplasia. However, dysplasia is a very imperfect predictor of
cancer risk for a number of reasons, including poor interobserver agreement among
pathologists in distinguishing dysplasia from reactive epithelial changes (caused by reflux
esophagitis) and in grading the severity of dysplastic change.84,106,107 Immunostaining for
p53 has been proposed as an adjunct to the diagnosis of dysplasia, but the utility of this
technique is limited by confounding factors such as high rates of false-positive staining and
staining characteristics that vary with the type of p53 antibody used.108 Immunostaining for
α-methylacyl-CoA racemase (AMACR) and for a panel of biomarkers that includes β-
catenin, cyclin D1, and p53 also has shown promise in preliminary studies for distinguishing
dysplasia from reactive changes and for distinguishing among grades of dysplasia.109–111 In
contrast to those promising reports, a study that attempted to correlate grades of dysplasia
with messenger RNA expression levels for a panel of 10 genes believed to contribute to
carcinogenesis in Barrett's esophagus found that the utility of the panel was severely limited
by significant interpatient and intrapatient variations in gene expression levels.112 At this
time, data supporting the use of biomarkers to confirm the histologic diagnosis of dysplasia
must be considered preliminary, and biomarkers cannot yet be recommended for this
purpose for routine clinical practice.
Can Biomarkers Be Used Instead of Dysplasia for Risk Stratification in
Barrett's Esophagus?—A number of biomarkers other than the histologic finding of
dysplasia have been proposed to predict the risk of neoplastic progression and, hence, the
need for endoscopic surveillance or more invasive treatments in patients with Barrett's
esophagus. In general, these putative biomarkers reflect DNA abnormalities, acquired during
the process of carcinogenesis, that either endow the cells with growth advantages directly or
favor the development of growth-promoting mutations. Most of the proposed biomarkers for
Barrett's esophagus have been evaluated in cross-sectional studies only, and no biomarker
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yet has been validated in prospective, controlled clinical trials. However, some biomarkers
have been evaluated in studies in which biopsy specimens of Barrett's metaplasia were
collected in a prospective systematic fashion, but the biomarker analyses were performed
retrospectively. Promising biomarkers that have been so evaluated include aneuploidy/
tetraploidy, 17p loss of heterozygosity (LOH), and several multiple biomarker panels.
Aneuploidy/tetraploidy: Genomic instability, which predisposes to the development of
cancer-causing mutations, can be manifested by gains or losses in parts of chromosomes, a
condition called aneuploidy. Aneuploidy can be detected in fresh frozen tissues by flow
cytometry and in esophageal brushings or paraffin-embedded tissues by fluorescence in situ
hybridization. Several reports suggest that flow cytometric evidence of aneuploidy and/or
increased tetraploidy (specimens in which the fraction of cells with 4 sets of chromosomes
exceeds 6%) can predict neoplastic progression in Barrett's esophagus more accurately than
the histologic grade of dysplasia.113–115
One study found that the 5-year cumulative incidence of cancer was 4% for patients with
Barrett's esophagus who had biopsy specimens showing no dysplasia, indefinite dysplasia,
or low-grade dysplasia (95% CI, 1.6–9.0).113 If the flow cytometry in those same cases was
normal, then the 5-year incidence of cancer was 0% (95% CI, 0–4.7); if the flow cytometry
showed aneuploidy or increased tetraploidy, then the 5-year incidence of cancer was 28%
(95% CI, 12.0–55.0). Thus, the results of flow cytometry provided more useful predictive
information on cancer than the histologic finding of no to low-grade dysplasia. For patients
with high-grade dysplasia, however, flow cytometry added little additional predictive
information. These findings were confirmed in a subsequent study by the same
investigators.114 The aforementioned studies suggest that aneuploidy or increased
tetraploidy might be used to predict the risk of cancer in patients who have Barrett's
esophagus with no dysplasia or only low-grade dysplasia. However, those studies detected
aneuploidy/tetraploidy by flow cytometry performed on frozen tissue specimens.
Esophageal biopsy specimens rarely are frozen in clinical practice, and high-quality flow
cytometry may not be widely available in clinical centers. These factors may have hindered
the adoption of aneuploidy/tetraploidy as a clinical biomarker for neoplastic progression in
Barrett's esophagus. In small studies, aneuploidy/tetraploidy detected by automated image
cytometry and fluorescence in situ hybridization, techniques that might be more feasible for
routine clinical practice, have been found to predict neoplastic progression in Barrett's
esophagus.116,117 These preliminary findings require validation in high-quality prospective
studies before the tests can be recommended for routine clinical application.
17p LOH: LOH for chromosome 17p, which harbors the p53 gene, also has shown promise
as a biomarker for neoplastic progression in Barrett's esophagus. In one study of patients
with Barrett's esophagus whose biopsy specimens showed changes ranging from no
dysplasia to high-grade dysplasia, the 3-year cumulative incidence of cancer was 38% (95%
CI, 26.0–54.0) for those with 17p LOH compared with only 3.3% (95% CI, 1.4–8.0) for
those with 2 intact 17p alleles.118 In the subset of patients who had no dysplasia, indefinite
dysplasia, or low-grade dysplasia, furthermore, 17p LOH was a significant predictor of
progression to high-grade dysplasia (RR, 3.6; 95% CI, 1.3–10). Other studies by the same
group of investigators confirm these findings.119
In the aforementioned studies, 17p LOH was detected using a labor-intensive technique in
which cells that were purified by flow cytometry were then subjected to whole-genome
amplification followed by genotypic analyses for LOH. More recently, cross-sectional
studies have shown promising results using simpler fluorescence in situ hybridization
analyses for 17p LOH on biopsy and brush cytology specimens of Barrett's
esophagus.120–123 However, one study that compared the techniques head to head found that
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fluorescence in situ hybridization had a lower sensitivity for detecting 17p LOH than the
flow cytometric approach.121
Biomarker panels: Numerous genetic abnormalities are acquired in variable sequences
during the process of carcinogenesis in Barrett's esophagus. Therefore, it is not surprising
that combinations of biomarkers in panels may be better at predicting the risk of neoplastic
progression than individual biomarkers. For example, one study found that patients with
Barrett's esophagus who had 3 biomarker abnormalities (aneuploidy/tetraploidy, 17p LOH,
and 9p LOH) in their esophageal biopsy specimens had an 80% incidence of cancer within 6
years, whereas those who had none of those abnormalities had an incidence of cancer of
only 12% at 10 years.119 Compared with the latter group, the RR of cancer progression for
patients with an abnormal biomarker panel was 38.7 (95% CI, 10.8–138.5).
A gene methylation-based biomarker panel also has shown promise for predicting
development of cancer in Barrett's esophagus. Promoter methylation is a process that can
silence the expression of a number of genes, including cancer-preventing tumor suppressor
genes. A study that evaluated methylation of a number of tumor suppressor genes in biopsy
specimens of Barrett's esophagus found that methylation of p16, RUNX3, and HPP1 was
associated with a significantly increased risk of progression to high-grade dysplasia or
cancer.124 The investigators generated a mathematical model for predicting neoplastic
progression in Barrett's esophagus that used the results of their methylation-based biomarker
panel (that included the aforementioned tumor suppressor genes), the patient's age, and the
extent of Barrett's metaplasia. When applied in a retrospective longitudinal fashion to a
cohort of patients with Barrett's esophagus, this prediction model was able to identify
patients destined to progress to high-grade dysplasia or cancer as early as 2 years before
neoplasia was recognized. Another more recent study has confirmed the ability of a
methylation-based biomarker panel to predict neoplastic progression in Barrett's
esophagus.125
In summary, a number of individual biomarkers and panels of biomarkers have been
proposed to predict the risk of neoplastic progression for patients with Barrett's esophagus.
To date, however, none of these has been validated in prospective, controlled clinical trials.
Available data on aneuploidy/tetraploidy and 17p LOH suggest that these biomarkers are no
better than the histologic finding of high-grade dysplasia for predicting progression of
cancer in Barrett's esophagus. However, aneuploidy/tetraploidy, 17p LOH, and methylation-
based biomarker panels may be superior to histology alone for risk stratifying those patients
with Barrett's esophagus whose initial biopsy specimens show no dysplasia, indefinite
dysplasia, or low-grade dysplasia. In certain circumstances, therefore, those biomarkers
could be used in combination with histology for risk stratification. Current data suggest that
the identification of aneuploidy by flow cytometry or the identification of 17p LOH by the
combination of flow cytometry, whole-genome amplification, and genotypic analysis are the
best available biomarker techniques. Thus, the routine clinical use of biomarkers instead of
dysplasia for risk stratification in Barrett's esophagus cannot be recommended at this time.
Nevertheless, it seems likely that the results of biomarker validation studies will be available
in the near future and that biomarkers eventually will be used to determine which patients
with Barrett's esophagus will benefit from endoscopic surveillance or ablative techniques.
Should Chromoendoscopy or “Electronic Chromoendoscopy” Be Used to Enhance the
Detection of Metaplasia and Dysplasia in Barrett's Esophagus?
The Seattle biopsy protocol for endoscopic surveillance in Barrett's esophagus, which
involves 4-quadrant biopsy sampling of every 1 to 2 cm of the columnar-lined esophagus, is
time consuming, labor intensive, costly, and subject to considerable sampling error. A
number of alternative endoscopic techniques have been proposed to enhance the detection of
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intestinal metaplasia and dysplasia in the esophagus. The ultimate goals for these advanced
imaging techniques are to improve the endoscopic detection of curable neoplasia in Barrett's
esophagus while reducing procedure time, expense, and sampling error.
Modern videoendoscopes use a charge-coupled device, which has a surface composed of
photosensitive elements (pixels). In high-resolution endoscopes, the charge-coupled device
has a large number of pixels (600,000 to 1,000,000) that provide detailed images of the
mucosal surface. High-resolution endoscopy can be combined with magnification devices
that enlarge the video image up to 150×.126–128 High-definition television systems, which
can generate up to 1080 scanning lines on a screen, enable the projection of a high-quality
image onto a large screen for ease of viewing.129 Compared with standard endoscopy, high-
resolution endoscopy appears to have higher sensitivity for detecting early neoplastic lesions
in Barrett's esophagus.130,131 Indeed, it is not clear that the image enhancement techniques
discussed in the following text add important information beyond that available by careful
white light inspection of the esophagus using high-resolution endoscopy.
Chromoendoscopy involves the application of chemical agents (eg, Lugol's solution,
methylene blue, indigo carmine, and acetic acid) that highlight various features of the
esophageal mucosa in an attempt to improve the detection of abnormalities.132–140 Lugol's
solution, which is taken up by esophageal squamous cells that contain glycogen, has been
used to highlight the squamocolumnar junction and as an aid for identifying residual islands
of Barrett's metaplasia (which are not stained by Lugol's solution) after endoscopic
eradication therapy.141 Reports on the use of methylene blue, which is absorbed by
intestinal-type epithelium that is not dysplastic, have described variable results. In a
prospective, randomized, crossover trial that compared methylene blue–directed biopsy with
standard 4-quadrant biopsy in 48 patients with Barrett's esophagus, the techniques were
found to be similar for the detection of intestinal metaplasia and dysplasia, although the
mean number of biopsies required to detect those conditions was significantly lower with
methylene blue staining.135 In contrast, another randomized crossover study found that the
4-quadrant biopsy technique detected dysplasia significantly more often than the methylene
blue–directed biopsy technique.136 A recent meta-analysis of 9 studies that included 450
total patients found that methylene blue staining and 4-quadrant biopsy techniques have
similar rates for detecting intestinal metaplasia and dysplasia.140 Further decreasing
enthusiasm for methylene blue staining is a study documenting that the technique causes
DNA damage in Barrett's epithelium.142
Different mucosal pit patterns in columnar epithelia can be recognized by combining
magnification endoscopy with the mucosal application of indigo carmine dye or acetic acid.
Using acetic acid, Guelrud et al described 4 pit patterns in Barrett's epithelium (round,
reticular, villous, and ridged) and found that the ridged and villous patterns were associated
with intestinal metaplasia.141 Sharma et al studied 80 patients with Barrett's esophagus using
indigo carmine and found that the ridged/villous mucosal pattern had high sensitivity (97%)
and reasonable specificity (76%) for intestinal metaplasia.138 In addition, all of 6 patients
with high-grade dysplasia were found to have a distorted or irregular glandular pattern.
However, a prospective, randomized, crossover study of 28 patients found that indigo
carmine chromoendoscopy did not increase the sensitivity for detecting early neoplasia in
Barrett's esophagus beyond that of high-resolution white light endoscopy.131
“Electronic chromoendoscopy” can be achieved by techniques such as narrow band imaging
(NBI), which uses spectral narrow-band optical filters to highlight vascular patterns on the
mucosal surface, or by optimal band imaging and I-scan, which use a postprocessing
technology to highlight contrast between squamous and columnar epithelia.143 In a
preliminary study of 24 patients with high-grade dysplasia or early cancer in Barrett's
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esophagus, optimal band imaging was found to detect neoplasia with a sensitivity of 87%
but with a positive predictive value of only 37%.144 Some single-center studies have
attempted to correlate the magnified NBI appearance of the mucosal glandular and vascular
patterns with the presence of metaplasia and dysplasia.145,146 In one such prospective study
of magnification NBI in 51 patients with Barrett's esophagus, a ridge/villous pattern
predicted the presence of intestinal metaplasia with a sensitivity of 93.5% and a specificity
of 86.7%, whereas an irregular/distorted pattern predicted high-grade dysplasia with a
sensitivity and specificity of 100% and 98.7%, respectively.145 The magnified NBI images
could not distinguish low-grade dysplasia from nondysplastic tissue, however. In another
study, Kara et al showed that areas of high-grade dysplasia in Barrett's esophagus had at
least one of 3 abnormal patterns by NBI: (1) an irregular/disrupted mucosal pattern, (2) an
irregular vascular pattern, and (3) abnormal blood vessels.146 A randomized crossover trial
that compared chromoendoscopy and NBI in 28 patients found no significant difference
between the 2 techniques for the detection of high-grade dysplasia and early cancer (93% vs
86% sensitivity), and neither technique was superior to high-resolution white light
endoscopy in that regard.131 In another study, endoscopists were asked to identify dysplasia
in still images of Barrett's epithelium taken during magnification endoscopy. The yield for
identifying dysplasia in images taken with high-resolution white light endoscopy was 86%,
and prediction rates did not increase significantly with the addition of either
chromoendoscopy or NBI.147
Two recent reports describe prospective studies that have compared the diagnostic yield of
NBI (nonmagnified) with that of white light endoscopy.148,149 In one study of 65 patients
who were known to have dysplasia in Barrett's esophagus, standard-resolution white light
endoscopy was performed first, followed by NBI performed by another endoscopist who
used NBI to detect and obtain biopsy specimens from areas suspicious for dysplasia.148 The
lesions initially detected by standard endoscopy were then disclosed and biopsy was
performed; finally, random 4-quadrant biopsy specimens were taken throughout the
columnar-lined esophagus. NBI was found to identify more patients with dysplasia than
standard-resolution white light endoscopy with random biopsy sampling (57% vs 43%; P < .
001). NBI also found higher grades of dysplasia significantly more often than standard
endoscopy (18% higher grade with NBI than with standard vs 0% higher grade with
standard than with NBI; P < .001). In a multicenter, randomized, crossover trial comparing
NBI-targeted biopsies with high-resolution white light endoscopy and 4-quadrant biopsies in
123 patients with Barrett's esophagus, there were no significant differences between the 2
techniques in the frequency of detecting intestinal metaplasia (85% for each technique) and
dysplasia (71% for NBI vs 55% for white light endoscopy; P = .15).149 However,
significantly fewer biopsies were required to establish a diagnosis with NBI (3.6 vs 7.6 per
procedure; P < .0001).
Chromoendoscopy for Barrett's esophagus is time consuming, fraught with technical
problems (eg, achieving uniform dye application), potentially hazardous (in the case of
methylene blue), poorly standardized (regarding the interpretation of mucosal patterns), and
subject to considerable interobserver variability. Studies comparing chromoendoscopy with
standard-resolution endoscopy have had contradictory findings, and studies have not
established any diagnostic advantage for chromoendoscopy beyond that which can be
achieved by high-resolution white light endoscopy. Consequently, we do not advocate the
routine use of chromoendoscopy in Barrett's esophagus. Electronic chromoendoscopy
techniques such as NBI are less time consuming and technically easier to perform than
chromoendoscopy but are still subject to problems of poor standardization and interobserver
variability. The studies discussed previously suggest that NBI may be superior to standard-
resolution white light endoscopy for detecting esophageal metaplasia and dysplasia, but
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studies so far have not established a convincing advantage for NBI over high-resolution
white light endoscopy.
We conclude that endoscopic surveillance is best performed with careful inspection of the
columnar-lined esophagus using high-resolution white light endoscopy, with biopsy
sampling of any lesions or suspicious areas so identified followed by 4-quadrant biopsy
sampling of the Barrett's metaplasia. The use of NBI or similar electronic chromoendoscopy
techniques cannot be advocated or discouraged at this time.
Should Advanced Endoscopic Imaging Techniques Such as Autofluorescence Imaging,
Confocal Laser Endomicroscopy, Diffuse Reflectance and Light Scattering Spectroscopy,
and Optical Coherence Tomography Be Used to Enhance the Detection of Metaplasia and
Dysplasia in Barrett's Esophagus?
Cells contain endogenous fluorophores (eg, reduced nicotinamide adenine dinucleotide,
porphyrins) that can absorb endoscopically delivered laser light and re-emit it as fluorescent
light with distinctive spectroscopic characteristics. Autofluorescence imaging (AFI) exploits
this phenomenon to highlight abnormal areas in Barrett's esophagus that can be targeted for
biopsy sampling.150–152 AFI attempts to distinguish normal from neoplastic epithelia based
on differences in their fluorescence spectra. An initial feasibility study found that AFI was a
sensitive test that improved the rate of detecting high-grade dysplasia but with poor
specificity that resulted in a positive predictive value of only 50%.150
In a multicenter study of 84 patients, Curvers et al explored the diagnostic potential of “tri-
modal imaging” in which the esophagus is first inspected by high-resolution white light
endoscopy, followed by AFI to rapidly highlight abnormal areas not detected by white light,
followed by NBI to confirm the abnormality of areas highlighted by AFI.152 High-resolution
white light endoscopy identified 16 patients with neoplasia, all of whom were also identified
by AFI. In addition, AFI detected 11 patients with early neoplasia who were not identified
by white light endoscopy. In total, AFI identified 102 abnormalities that were not seen by
white light endoscopy, but with poor specificity resulting in a false-positive rate for
neoplasia detection of 81%. That false-positive rate was reduced to 26% by NBI
examination. However, multi-modality imaging also missed neoplasia in 3 patients (10%)
for whom the condition was detected only by random 4-quadrant biopsies.
Confocal laser endomicroscopy involves examination of the gut mucosa using
endoscopically delivered laser light, which is reflected back through a pinhole onto sensors
that relay the signals to a computer, which translates the information into a cross-sectional
microscopic image of the mucosa.153–158 Magnifications even beyond 1000× can be
achieved with confocal laser endomicroscopy, allowing for real-time microscopic analysis
of mucosal crypt architecture and capillaries. The use of this system with ultra-high
magnifications (450× and 1125×) to evaluate individual cellular and subcellular structures
has been called “endocytoscopy.”159,160
Initial reports on confocal laser endomicroscopy from a single center, using a confocal laser
endomicroscopy device integrated into the tip of a conventional videoendoscope, described
excellent accuracy rates (85%–94%) for the detection of high-grade dysplasia in patients
with Barrett's esophagus, most of whom had abnormalities seen by white light
endoscopy.153,156 Another group used a probe-based confocal laser endomicroscopy device
to study patients who had Barrett's esophagus without visible lesions and observed that the
finding of fused glands identified advanced neoplasia with a sensitivity of 80% and with
good interobserver agreement, as evidenced by a κ value of 0.6.154 In an ex vivo study of
166 biopsy specimens from 16 patients, the positive and negative predictive values of
endocytoscopy for high-grade dysplasia/early cancer were found to be 44% and 83%,
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respectively.160 At 1125× magnification, however, adequate assessment of endocytoscopy
images was not possible in 22% of the target areas.
Both diffuse reflectance spectroscopy and light scattering spectroscopy have been used to
study Barrett's esophagus. Diffuse reflectance spectroscopy analyzes light that has been
scattered multiple times within the tissue before it is detected by the sensing device, whereas
light scattering spectroscopy analyzes light that is scattered back to the sensing device after
undergoing only a single scattering event. Algorithms have been developed to use the
spectroscopic information so collected to distinguish nonneoplastic and neoplastic regions in
Barrett's esophagus.161–163 Using the diffuse reflectance spectra collected from 16 patients,
one diagnostic algorithm was able to distinguish high-grade dysplasia from low-grade
dysplasia and nondysplastic tissue in Barrett's esophagus with a sensitivity of 86% and a
specificity of 100%.161 The sensitivity and specificity for separating any grade of dysplasia
from no dysplasia were 79% and 88%, respectively. Using light scattering spectroscopy data
for 76 sites in 13 patients with Barrett's esophagus, Wallace et al found that a diagnostic
algorithm based on nuclear enlargement had a sensitivity and specificity of 90% in
distinguishing dysplastic from nondysplastic tissue.163
Optical coherence tomography uses near-infrared light to provide high-resolution cross-
sectional imaging of the esophageal mucosa.164 The technique is similar in principle to
endosonography, but image formation in optical coherence tomography depends on
variations in the reflectance of light (rather than ultrasonic waves) from different tissue
layers.165–168 In an initial study of 121 patients with Barrett's esophagus, objective image
criteria for Barrett's metaplasia (without dysplasia) were formulated on the basis of data
obtained from 166 optical coherence tomography images that had corresponding biopsy
specimens.166 Data from this training set were validated using 122 optical coherence
tomography images that were obtained prospectively. The optical coherence tomography
criteria so developed were found to have a sensitivity and specificity of 97% and 92%,
respectively, for the identification of Barrett's metaplasia.
The studies discussed previously describe some promising preliminary results for the
advanced imaging techniques in the detection of esophageal metaplasia and dysplasia. To
date, however, these advanced techniques have not been shown to provide additional clinical
information (beyond that available by high-resolution white light endoscopy) sufficient to
warrant their routine application in clinical practice.
Should Proton Pump Inhibitors Be Used for Chemoprevention in Barrett's Esophagus?
Should Nonsteroidal Anti-inflammatory Drugs Be Used for Chemoprevention in Barrett's
Esophagus?
Should Proton Pump Inhibitors Be Used for Chemoprevention in Barrett's
Esophagus?—Chemoprevention involves the use of a pharmacologic agent to prevent the
development of cancer.169 Whereas the process of carcinogenesis in Barrett's esophagus
may span decades, studies on potential chemopreventive agents generally have evaluated the
effects of those agents on surrogate markers for cancer development, such as dysplasia,
rather than on the development of cancer itself. The validity of using such surrogate end
points is not clear. Furthermore, although a number of agents have been proposed for
chemoprevention in Barrett's esophagus, only one has been evaluated in prospective,
randomized, controlled clinical trials. Based on available data, the most promising
chemopreventive agents for this condition appear to be the proton pump inhibitors (PPIs)
and the nonsteroidal anti-inflammatory drugs (NSAIDs).
The evidence to support potent acid suppression with PPIs as a chemopreventive strategy in
Barrett's esophagus is largely indirect. In certain ex vivo and in vitro model systems, for
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example, acid has been shown to damage DNA and to induce proproliferative and
antiapoptotic effects.170–173 By inference, therefore, gastric acid inhibition should be
beneficial. A number of observational studies have found an inverse correlation between
long-term use of PPIs and the incidence of dysplasia and adenocarcinoma in patients with
Barrett's esophagus.174–177 Some prospective clinical studies have shown that PPI therapy is
associated with a decrease in proliferation markers, a potentially cancer-protective effect, in
biopsy specimens of Barrett's metaplasia.178–180 Unfortunately, prospective clinical studies
have yet to prove that PPI therapy can prevent the development of dysplasia and its
progression in Barrett's esophagus.
PPI therapy also has effects that, conceivably, might promote the development of cancer in
Barrett's esophagus. For example, use of PPIs often is associated with an increase in the
serum levels of gastrin, a hormone that has been shown to increase proliferation in Barrett's
epithelium. Epidemiologic studies that have attempted to seek a cancer-promoting effect for
PPIs have encountered the problem of confounding by indication, because long-term PPI
therapy often is prescribed to treat GERD, which is a risk factor for esophageal
adenocarcinoma. Thus, an association between PPIs and cancer may have nothing to do with
the PPI, but rather may result from the underlying GERD for which the PPI is prescribed.
Using the large general practitioners research database in the United Kingdom, for example,
Garcia Rodriguez et al found that patients who were treated with acid suppression for an
“esophageal indication” such as GERD had a significantly increased risk of developing
esophageal adenocarcinoma (odds ratio, 5.42; 95% CI, 3.13–9.39).181 In contrast, for
patients who were treated with acid suppression for a “gastroduodenal indication” such as
peptic ulcer disease, there was no significantly increased risk of adenocarcinoma (odds ratio,
1.74; 95% CI, 0.90–3.34). The lack of an association with cancer in patients taking PPIs for
gastroduodenal disease suggests that the positive association in the patients with esophageal
disease resulted from confounding by indication. In other words, it was likely the GERD,
not the GERD treatment, that increased the incidence of cancer. Other studies on this issue
also have not found a significant association between esophageal adenocarcinoma and the
use of antisecretory agents per se.182,183
In summary, available circumstantial evidence supports the use of PPIs as a
chemopreventive strategy in patients with Barrett's esophagus. Few would argue the need for
PPIs to control GERD symptoms and to heal reflux esophagitis for these patients. However,
insufficient data are available to support the practice of prescribing PPIs in dosages higher
than those needed to eliminate the symptoms and endoscopic signs of GERD or, for patients
with no such symptoms and signs, in dosages higher than those recommended as
conventional for the treatment of GERD. Similarly, insufficient data are available to support
the practice of using esophageal pH monitoring to titrate PPI dosing so as to normalize
esophageal acid exposure for patients with Barrett's esophagus.
Should Nonsteroidal Anti-Inflammatory Drugs Be Used for Chemoprevention
in Barrett's Esophagus?—Multiple lines of evidence suggest that aspirin and other
NSAIDs protect against esophageal adenocarcinoma. There are data to suggest that NSAIDs
exert their antitumor effects both through the inhibition of cyclooxygenase-2 and through
actions independent of cyclooxygenase inhibition.184,185 In vitro studies have shown that
NSAIDs can decrease cellular proliferation, increase apoptosis, and interfere with
angiogenesis, effects that would be expected to prevent cancer formation.186–189 In animal
models of GERD, NSAIDs have been found to decrease the development of Barrett's
esophagus and esophageal adenocarcinoma.190–192 In addition, decreased proliferation has
been documented in biopsy specimens of Barrett's epithelium taken from patients who were
treated with rofecoxib, a cyclooxygenase-2 selective NSAID.193 Irrespective of the
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underlying mechanism, ample experimental data suggest that NSAIDs may be effective
chemopreventive agents for patients with Barrett's esophagus.
A number of epidemiologic studies also have supported the use of aspirin and other NSAIDs
as chemopreventive agents in Barrett's esophagus. A meta-analysis of such studies by Corley
et al found that the use of NSAIDs was associated with a 33% reduction in the risk of
developing esophageal adenocarcinoma (odds ratio, 0.67; 95% CI, 0.51–0.87), and both
aspirin and nonaspirin NSAIDs appeared to be equally effective in this regard.194 More
recent studies on this issue have yielded contradictory results, however. A questionnaire-
based study that included approximately 300,000 members of AARP found no significant
association between esophageal adenocarcinoma and the use of aspirin (1.00; 95% CI, 0.73–
1.37) or nonaspirin NSAIDs (0.90; 95% CI, 0.69–1.17).195 In contrast, Vaughn et al
prospectively studied a cohort of 350 patients with Barrett's esophagus followed up for
20,770 person-months and found that, compared with those who never used NSAIDs,
current users of NSAIDs had a significantly decreased risk of esophageal adenocarcinoma
(hazard ratio, 0.20; 95% CI, 0.10–0.41).196 Finally, Heath et al randomized 100 patients who
had either low- or high-grade dysplasia in Barrett's esophagus to receive either the
cyclooxygenase-2 selective NSAID celecoxib 200 mg twice daily (49 patients) or placebo
(51 patients). After 48 weeks of treatment, there was no significant difference between the 2
groups in the proportion of esophageal biopsy specimens showing dysplasia or cancer.197
However, this study had a number of limitations (eg, the use of dysplasia as the primary
outcome, the use of a low dose of celecoxib) that may have affected the outcome.
Limited data suggest that biomarkers might have a role in identifying those patients with
Barrett's esophagus who are most likely to benefit from chemopreventive therapies. For
patients with Barrett's esophagus with DNA content abnormalities, 17p LOH, and/or 9p
LOH in their esophageal biopsy specimens, for example, one study found that the use of
NSAIDs was associated with a significant reduction in the risk of esophageal
adenocarcinoma at 6 and 10 years of follow-up.119 In contrast, no beneficial effect of
NSAIDs was seen in those patients whose biopsy specimens had none of those
abnormalities.
NSAIDs clearly have substantial potential for toxicity, including serious gastrointestinal and
cardiovascular side effects, and it is not clear whether the potential cancer-preventive effects
warrant those risks. Even use of low-dose aspirin has been associated with serious bleeding
complications. A meta-analysis of randomized controlled trials comparing low-dose aspirin
(75–325 mg) and placebo for cardiovascular prophylaxis found that the absolute annual
increase in risk attributable to aspirin was only 0.13% (95% CI, 0.08–0.20) for major
bleeding, 0.12% (95% CI, 0.07–0.19) for major gastrointestinal bleeding, and 0.03% (95%
CI, 0.01–0.08) for intracranial bleeding.198 Thus, the overall risk of using low-dose aspirin
is small. Moreover, patients included in that meta-analysis were not receiving concomitant
PPI therapy, which has been shown to reduce the risk of gastrointestinal bleeding with low-
dose aspirin by a factor of 2 to 9.199,200 Typically, the diagnosis of Barrett's esophagus is
made in men older than 50 years of age and, as discussed previously, those patients may be
at increased risk for cardiovascular disease. Low-dose aspirin has been shown to be
beneficial for primary cardiovascular events in men older than 50 years of age who are at
risk for developing coronary artery disease.201,202 Thus, low-dose aspirin has the potential
to prevent cardiovascular events as well as esophageal cancer.
In summary, most available reports suggest that aspirin and other NSAIDs protect against
the development of cancer in Barrett's esophagus, but definitive studies are lacking.
Presently, we believe that it is appropriate to consider the prescription of low-dose aspirin
for patients with Barrett's esophagus who also have risk factors for cardiovascular disease.
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Whereas patients will already be taking a PPI, the risks of aspirin causing serious
gastrointestinal toxicity in average-risk individuals should be minimal. A large, prospective,
randomized clinical trial in the United Kingdom is investigating the chemopreventive effects
of PPIs alone and in combination with aspirin (AspECT), and the results of that study are
eagerly awaited.203
Should Antireflux Surgery Be Advised to Prevent Cancer in Barrett's Esophagus?
For many patients with Barrett's esophagus, PPI therapy eliminates GERD symptoms, but
esophageal acid exposure remains abnormal nevertheless.204–206 In one study of 48 patients
with Barrett's esophagus who had been rendered asymptomatic by PPI treatment, for
example, 50% had persistently abnormal acid exposure documented by esophageal pH
monitoring.206 Even if PPIs normalize acid reflux, the reflux of nonacidic gastric material
persists and, conceivably, bile and other noxious agents in that refluxed material might
contribute to carcinogenesis in Barrett's esophagus. As noted previously, furthermore, PPIs
themselves have effects that, in theory, might promote development of cancer (eg, elevated
serum gastrin levels, bacterial colonization of the stomach). For all these reasons, it has been
proposed that fundoplication, which is designed to eliminate gastroesophageal reflux, might
be more effective than antisecretory therapy for preventing cancer in Barrett's esophagus.207
A number of observational studies have described fewer cases of dysplasia and cancer
developing in patients with Barrett's esophagus who had antireflux surgery than in those
who had received medical treatment.208–210 Those studies generally have been small and
subject to numerous biases that might inflate the benefits of surgical therapy. Higher-quality
studies have not found that antireflux surgery is superior to medical therapy for prevention
of cancer in Barrett's esophagus.
During 10 to 13 years of follow-up for patients (many of whom had Barrett's esophagus)
who had participated in a randomized trial of medical and surgical therapies for GERD, 4 of
165 patients (2.4%) in the medical group and 1 of 82 (1.2%) in the surgical group developed
an esophageal adenocarcinoma.211 The difference between the treatment groups in the
incidence of this malignancy was not statistically significant but, with such a low observed
rate of cancer development, the study did not have sufficient statistical power to detect a
small cancer-protective effect for fundoplication.
Two studies using large patient databases212,213 and 3 meta-analyses22,214,215 also have
found no significant cancer-preventive effect for antireflux surgery. In one meta-analysis,
Chang et al initially found that the incidence of esophageal adenocarcinoma in Barrett's
esophagus was significantly lower in surgically treated patients (2.8 [95% CI, 1.2–5.3] per
1000 patient-years) than in medically treated patients (6.3 [95% CI, 3.6–10.1]; P = .034).22
However, the investigators found that there was significant heterogeneity in the cancer
incidence rates reported in case series compared with the higher-quality controlled studies
(P = .014). In the controlled studies, there were no significant differences in cancer
incidence rates between surgically and medically treated patients (4.8 [1.7–11.1] vs 6.5 [2.6–
13.8] per 1000 patient-years, respectively; P = .32). The authors concluded that evidence
suggesting that surgery reduced the risk of cancer in Barrett's esophagus was driven largely
by uncontrolled studies.
In summary, there is no convincing evidence that antireflux surgery is more effective than
medical therapy for prevention of cancer in Barrett's esophagus. We conclude that antireflux
surgery should not be advised with the rationale that the procedure will prevent esophageal
cancer.
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What Is the Role for EMR in Barrett's Esophagus? Should Endoscopic Eradication Be
Used to Treat Patients Who Have Barrett's Esophagus Without Dysplasia? Should
Endoscopic Eradication Be Used to Treat Patients Who Have Barrett's Esophagus With
Low-Grade Dysplasia? Should Endoscopic Eradication Be Used to Treat Patients Who
Have Barrett's Esophagus With High-Grade Dysplasia or Intramucosal Carcinoma?
What Is the Role for EMR in Barrett's Esophagus?—In EMR, a diathermic snare or
endoscopic knife is used to remove Barrett's metaplasia down to the submucosa, providing
large tissue specimens that can be used to assess the depth of any neoplastic involvement
and the adequacy of the resection. Thus, EMR has potential value as both a diagnostic/
staging procedure and as a therapeutic procedure for removing Barrett's epithelium with and
without neoplasia.
In surgical series of patients who have undergone esophagectomy for the treatment of high-
grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus, lymph node
metastases have been described in 0% to 7%.216–220 For patients whose tumors extend into
the submucosa, however, the frequency of lymph node metastases often exceeds
20%.216,217,220 For this reason, endoscopic therapy generally is not considered definitive for
patients with neoplasms that involve the submucosa. When considering endoscopic
eradication therapy for neoplasia in Barrett's esophagus, therefore, accurate T staging is
essential. Although endoscopic ultrasonography (EUS) is considered the most accurate
imaging modality for the T staging of gastrointestinal cancers, standard EUS accurately
predicts the depth of invasion for early esophageal cancers in only 50% to 60% of cases.221
Even high-frequency probe EUS is inadequate in this situation, as evidenced by one study of
9 patients who underwent esophagectomy for early neoplasia in Barrett's esophagus in
whom preoperative T staging by high-frequency probe EUS was found to be accurate in
only 4 cases.222
In a study of 40 patients with neoplasia in Barrett's esophagus who had EMR performed
after endoscopic biopsy and EUS, histologic review of the EMR specimen revealed
intramucosal carcinoma in 24% of patients with an EUS/biopsy diagnosis of high-grade
dysplasia and invasive cancer in 40% of patients with an EUS/biopsy diagnosis of
intramucosal carcinoma.223 In a study in which preoperative EMR findings were compared
with subsequent histologic examination of esophagectomy specimens for 25 patients with
high-grade dysplasia or adenocarcinoma in Barrett's esophagus, there was perfect agreement
in T staging by EMR and esophagectomy.224 These studies show that EMR can be
considered a valuable diagnostic/staging procedure for identifying submucosal invasion that
might not be apparent by less invasive techniques such as mucosal biopsy and EUS.
In addition to its role in staging neoplasms in Barrett's esophagus, EMR also has been used
to eradicate Barrett's epithelium, high-grade dysplasia, and early Barrett's cancers. Cohort
studies have found that EMR can achieve complete eradication of Barrett's epithelium in
75% to 100% of cases and complete eradication of dysplasia in 86% to 100% of
cases.225–232 At this time, there are no published randomized trials comparing EMR with
other endoscopic therapies for the eradication of Barrett's epithelium.
Should Endoscopic Eradication Be Used to Treat Patients Who Have Barrett's
Esophagus Without Dysplasia?—Endoscopic eradication therapy for Barrett's
esophagus includes EMR and/or the endoscopic ablative techniques, which use thermal,
photochemical, or radiofrequency energy to destroy the Barrett's epithelium without
providing a tissue specimen. Following ablation or EMR, patients are prescribed antireflux
therapy (usually PPIs) so that the eradicated esophageal mucosa heals with the growth of
new squamous epithelium (also called neo-squamous epithelium). Endoscopic ablation for
Barrett's esophagus was first described in 1992, and early feasibility studies were conducted
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in patients with nondysplastic Barrett's esophagus. Presently, endoscopic therapies are being
used primarily to treat patients with dysplasia and early adenocarcinoma in Barrett's
esophagus.
The earliest studies of endoscopic ablative therapy used lasers to destroy nondysplastic
Barrett's epithelium. Since then, the techniques that have been studied most extensively for
the eradication of Barrett's esophagus without dysplasia include multi-polar
electrocoagulation (MPEC), argon plasma coagulation (APC), and radiofrequency ablation
(RFA).233–243 Most reports of such studies describe case series, and there is considerable
heterogeneity among those studies regarding the primary end points (eg, complete
eradication, partial eradication, percentage regression of Barrett's metaplasia), the duration
of follow-up, and the postablation surveillance protocols.
For MPEC, several prospective case series have described the complete eradication of
nondysplastic Barrett's epithelium in 65% to 100% of cases. In a study involving only 14
patients, Montes et al reported a complete eradication rate of 100% during a mean follow-up
of 21.6 months.233 In contrast, another study of 58 patients followed up for 6 months found
a complete eradication rate of only 78%.234
For APC, the complete eradication of nondysplastic Barrett's esophagus has been described
in 36% to 100% of cases, with recurrences found in up to 66% of the treated patients. In a
cohort of 70 patients treated with APC and followed up for a median of 51 months, Madisch
et al reported a complete eradication rate of 98%, with a recurrence rate of 12%.237 In
contrast, another study of 25 patients treated with APC noted an initial complete eradication
rate of only 84% and found a recurrence rate of 66% during a median follow-up period of 30
months.238 Manner et al used high-power (90 W) APC to treat 51 patients who had Barrett's
esophagus without dysplasia.243 Nine of the 51 patients (18%) experienced transient side
effects, including chest pain, fever, and odynophagia. Five patients (10%) had a major
complication, including hemorrhage (2 patients), esophageal stricture (2 patients), and
esophageal perforation (1 patient). During a mean follow-up of 14 months, complete
eradication of Barrett's epithelium was achieved in 37 of the 48 patients (77%) who had
follow-up examinations.
Bright et al randomized 40 patients with Barrett's esophagus who had undergone antireflux
surgery to receive either APC or endoscopic surveillance without ablative therapy.240
During a median follow-up period of 68 months, complete eradication of Barrett's
epithelium was achieved in 40% of patients treated with APC compared with 20% in the
surveillance group. One patient treated with APC was found to have progression to low-
grade dysplasia, whereas 2 patients in the surveillance group developed low-grade dysplasia
and another 2 progressed to high-grade dysplasia during the same period of follow-up.
Two randomized trials have compared MPEC and APC for the treatment of Barrett's
esophagus without dysplasia. In a study of 35 such patients followed up for 2 years, Sharma
et al found no significant differences in the percentage of complete eradication for 16
patients treated with MPEC (75% complete eradication) compared with 19 patients treated
with APC (63% complete eradication; P = .49).235 Both techniques required multiple
treatment sessions (4 for MPEC vs 3 for APC; not significant), and no factors were
identified that could be used to predict complete eradication. The other randomized trial
involved 52 patients and also found no significant differences between the treatment groups
in the percentage of complete eradication (81% for MPEC vs 65% for APC; P = .21).236
In another comparative trial, 68 patients who had Barrett's esophagus without dysplasia were
randomized to receive treatment with either APC or photodynamic therapy (PDT) using 5-
aminolevulinic acid as the photosensitizer. During a median follow-up period of 12 months,
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complete eradication was noted in 97% of patients in the APC group compared with only
50% of patients who received PDT (P < .0001).239
RFA therapy uses a balloon-based circumferential array of closely spaced electrodes to
deliver radiofrequency energy to the esophageal mucosa. This system was designed with the
intent of inflicting a uniform circumferential thermal injury with depth that is controlled by a
generator, which can vary the power, density, and duration of the energy applied. In one
study of 70 patients who had Barrett's esophagus without dysplasia, RFA resulted in
apparent complete eradication of Barrett's epithelium in 69% of patients at 12 months.241
Noting the problem of frequent incomplete eradication, the RFA manufacturer introduced a
smaller, endoscope-mounted, radiofrequency catheter ablation device to be used for the
focal ablation of metaplasia that remains behind after treatment with the circumferential
system. In a 30-month follow-up study of the same cohort described in the aforementioned
report, use of the focal ablative device resulted in the complete eradication of Barrett's
epithelium in 97% of the patients.242
The reports described previously establish that endoscopic ablative therapies can eradicate
nondysplastic Barrett's epithelium in the short-term for the majority of patients. However,
those reports do not establish the benefit of that eradication. Some reports describe a high
rate of recurrent metaplasia, and it is not clear that any ablative procedure provides long-
term protection from esophageal cancer. A recent cost-utility analysis suggests that ablation
of nondysplastic Barrett's epithelium could be a preferred management strategy if the
procedure eliminates the need for long-term endoscopic surveillance, with its attendant risks
and expense.244 However, in the absence of long-term studies showing efficacy, it is not
clear that surveillance should be discontinued after ablation therapy. Consequently, it is not
clear that the potential benefit of ablation in reducing the small risk of cancer for patients
who have Barrett's esophagus without dysplasia warrants the risks and substantial expense
of the ablative procedures.
Should Endoscopic Eradication Be Used to Treat Patients Who Have Barrett's
Esophagus With Low-Grade Dysplasia?—Few studies have focused exclusively on
the efficacy of endoscopic eradication for patients with low-grade dysplasia in Barrett's
esophagus. Rather, such patients commonly have been included as a subgroup in eradication
trials that have involved primarily patients without dysplasia or patients with high-grade
dysplasia, a feature that can confound the interpretation of study results. Overall, eradication
rates for low-grade dysplasia have ranged from 35% to 100%, with a similar range for
recurrence rates.
One study that used APC to ablate dysplastic Barrett's epithelium found complete
eradication of low-grade dysplasia in all of 19 patients followed up for a median of 12
months.245 Using PDT with 5-aminolevulinic acid, Ackroyd et al completely eradicated
low-grade dysplasia in all of 40 patients during a mean follow-up of 53 months.246 Another
study using PDT, this time with sodium porfimer (n = 14), found complete eradication of
low-grade dysplasia in 13 of 14 patients (93%) followed up for a mean of 50.7 months.247 A
randomized trial that compared the efficacies of APC and PDT (with porfimer sodium) for
treating low-grade dysplasia found substantially lower rates of complete eradication (62%
with APC vs. 77% with PDT), with no significant difference between the 2 treatment groups
in the frequency of complete eradication.248 In a recent single-center study that used RFA to
treat 39 patients with low-grade dysplasia, complete eradication of dysplasia was achieved
in 95%, and 87% had complete eradication of Barrett's metaplasia during a median follow-
up of 24 months.249
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Recently, Shaheen et al reported the results of a multicenter, prospective, randomized, sham-
controlled trial on endoscopic eradication that included 64 patients with low-grade dysplasia
in Barrett's esophagus who were randomized to receive either RFA (42 patients) or a sham
procedure (22 patients).250 At 12 months, complete eradication of low-grade dysplasia was
achieved in 90% of patients in the RFA group compared with 23% in the sham group (P < .
001). Complete eradication of Barrett's metaplasia was achieved in 81% and 4% of the RFA
and sham groups, respectively (P < .001). During the trial period, however, there was no
significant difference between the RFA and sham treatment groups in the percentage of
patients who had progression from low-grade to high-grade dysplasia (5% in the RFA group
and 14% in the sham group; P = .33), and no patient with low-grade dysplasia in either
group progressed to cancer.
The conclusions that can be drawn from studies on endoscopic eradication therapy for low-
grade dysplasia are similar to those for the eradication of nondysplastic Barrett's esophagus
discussed previously. Available reports establish that ablative therapies can eradicate low-
grade dysplasia in the short-term for the majority of patients, but the reports do not establish
the benefit of that eradication. Difficulties in verifying a diagnosis of low-grade dysplasia
(see the previous text) and uncertainty regarding its natural history further confound the
situation. In the absence of long-term studies showing efficacy, it is not clear that the
potential benefit of ablation in reducing cancer risk for patients who have Barrett's
esophagus with low-grade dysplasia warrants the risks and substantial expense of the
ablative procedures.
Should Endoscopic Eradication Be Used to Treat Patients Who Have Barrett's
Esophagus With High-Grade Dysplasia or Intramucosal Carcinoma?—In a
recent study of 39 patients with neoplasia in Barrett's esophagus (25 high-grade dysplasia,
14 early cancers), sequential EMR (mean of 3 sessions) resulted in complete eradication of
neoplasia in all patients and complete eradication of Barrett's epithelium in 89%, with no
recurrences observed during a median follow-up of 11 months.251 The largest reported
experience with EMR as the primary technique to eradicate high-grade dysplasia and early
cancer in Barrett's esophagus involved 349 patients followed up for a mean of 63.6
months.232 The early complete eradication rate for neoplasia was 97%, but metachronous
neoplasms subsequently developed in 21.5% of patients; 85% of those patients received
further endoscopic eradication therapy and achieved a second complete remission. Risk
factors for metachronous neoplasms identified in this study included piecemeal resection of
the lesion (RR, 2.4; 95% CI, 1.13–4.89), long-segment Barrett's esophagus (RR, 1.9; 95%
CI, 1.06–3.3), no use of mucosal ablative therapies after EMR (RR, 2.5; 95% CI, 1.52–
3.85), time until complete remission achieved greater than 10 months (RR, 0.3; 95% CI,
0.12–0.75), and multifocal neoplasia (RR, 2.1; 95% CI, 1.16–3.9).
For the treatment of high-grade dysplasia in Barrett's esophagus, PDT was the first
endoscopic ablative modality to be evaluated in a randomized controlled trial. In that trial,
208 patients with high-grade dysplasia were randomized either to the control group, which
received treatment with omeprazole alone, or to the group that received treatment with PDT
(using porfimer sodium as the sensitizing agent) plus omeprazole. In the initial report of this
study, when the duration of follow-up was 2 years, the primary goal of complete eradication
of high-grade dysplasia was achieved in 77% of patients in the PDT group compared with
39% of patients in the control group (P < .0001).252 In a subsequent follow-up study of
those patients at 5 years, intention-to-treat analyses showed that PDT was significantly more
effective than omeprazole alone for eradicating high-grade dysplasia (77% [106/138] vs
39% [27/70]; P < .0001) and that PDT-treated patients were less likely to progress to cancer
(15% vs 29%; P = .027), although the trial was not designed specifically to test this
outcome.253 In addition to this randomized controlled trial, a number of small uncontrolled
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studies of PDT (using 5-aminolevulinic acid as the sensitizing agent) for the treatment of
high-grade dysplasia or early cancer in Barrett's esophagus have found complete eradication
rates ranging from 77% to 100%.254,255
Reports of uncontrolled studies have described promising results for RFA for patients with
high-grade dysplasia in Barrett's esophagus. In a single-center study in which 24 patients
with high-grade dysplasia were treated with RFA and followed up for up to 24 months,
complete eradication of dysplasia and intestinal metaplasia was found in 79% and 67% of
patients, respectively.249 A multicenter registry of 142 patients with high-grade dysplasia
treated with RFA therapy described complete eradication of dysplasia and intestinal
metaplasia in 90% and 54% of patients, respectively.256
The previously mentioned prospective, sham-controlled trial of RFA by Shaheen et al
included 63 patients with high-grade dysplasia in Barrett's esophagus who were randomized
to receive either RFA (42 patients) or a sham procedure (21 patients).250 At 12 months, after
an average of 3.5 endoscopic sessions, complete eradication of high-grade dysplasia was
achieved in 81% of patients in the RFA group compared with 19% in the sham group (P < .
01). Complete eradication of Barrett's metaplasia was achieved in 74% and 0% of the RFA
and sham groups, respectively (P < .001). Furthermore, 4 patients in the sham group
progressed to cancer compared with only 1 in the RFA group (P = .04).
Reports of small studies have described the use of cryotherapy and APC to eradicate high-
grade dysplasia and early cancer in Barrett's esophagus.257,258 In a prospective trial that
used CryoSpray in 31 patients (26 with high-grade dysplasia, 5 with early cancer), complete
eradication of neoplasia and intestinal metaplasia was achieved at 12 months in 23% and 1%
of patients, respectively.258 Although these results may seem unimpressive, it should be
noted that 27% of the patients had previous unsuccessful attempts at endoscopic eradication
with other modalities. Attwood et al used APC in 29 patients with high-grade dysplasia and
reported complete eradication of dysplasia and intestinal metaplasia in 86% and 76% of
patients, respectively.259 However, 4 patients developed cancer during a 37-month follow-
up period.
Most of the studies discussed previously on endoscopic ablation of neoplasia in Barrett's
esophagus have evaluated the results of a single ablative technique performed without EMR.
However, an emerging concept in the endoscopic management of neoplasia in Barrett's
esophagus is that endoscopic eradication may be best effected by first removing visible
abnormalities with EMR, which provides invaluable staging information as well as therapy,
followed by the ablation of all remaining Barrett's metaplasia. In the aforementioned study
by Pech et al on endoscopic eradication therapy for patients with high-grade dysplasia or
intramucosal carcinoma in Barrett's esophagus, metachronous neoplasms were detected
during follow-up in 30% of 137 patients treated with EMR alone, whereas metachronous
neoplasms were found in only 17% of 200 patients who were treated with EMR followed by
ablation with APC or PDT.232 In a recent multicenter European trial, 23 patients with
neoplasia in Barrett's esophagus (7 with high-grade dysplasia, 16 with early cancer) had
EMR followed by RFA.260 At a median follow-up of 22 months, complete eradication of
neoplasia and intestinal metaplasia was achieved in 95% and 88% of patients, respectively.
Major complications of endoscopic eradication therapy for Barrett's esophagus include
esophageal stricture formation, bleeding, and perforation. Minor complications include
transient chest pain, fever, and odynophagia. After PDT and RFA, esophageal stricture
development has been reported in up to 36% and 6% of patients, respectively.250,258 After
EMR, esophageal stricture formation has been observed primarily in patients treated with
circumferential resections that were aimed at eliminating all Barrett's epithelium.227,229
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Rates of bleeding with the various modalities have varied from 0 to 10%, and perforations
are uncommon.
Although a number of studies describe complete elimination of all Barrett's epithelium after
endoscopic eradication therapy, this claim is suspect because it is based on endoscopic
appearance and on random biopsy sampling techniques. These practices do not eliminate the
possibility that the eradication procedure caused squamous epithelium to grow over foci of
Barrett's epithelium (so-called “buried” metaplasia), which may retain malignant potential.
Buried metaplasia easily can be missed as the result of biopsy sampling error, and
superficial biopsy specimens of squamous epithelium that do not provide at least some
lamina propria are not informative for buried metaplasia. Indeed, without resecting the
esophagus and examining its full thickness histologically, it is virtually impossible to
exclude the presence of buried metaplasia. A recent systematic review found that buried
metaplasia was associated with dysplasia or cancer in the buried glands in 0 to 30% of
patients in studies on endoscopic eradication therapy.261
One recent study suggests that the risk of buried metaplasia following eradication therapy
may be exaggerated, because buried metaplasia can be found with similar frequency in
patients who are treated with PPIs alone (without endoscopic ablation). Bronner et al
examined biopsy specimens of esophageal squamous epithelium taken during the previously
mentioned randomized trial of PDT for patients with high-grade dysplasia in Barrett's
esophagus.262 After reviewing 33,658 esophageal biopsy specimens, the investigators found
no significant difference in the frequency of squamous overgrowth (buried metaplasia)
between the group treated with PDT (39 of 132 patients; 30%) and the group that received
omeprazole alone (22 of 67 patients; 33%; P > .05). Furthermore, the highest grade of
neoplasia per endoscopy was not found exclusively in the buried metaplasia in any patient.
Apparently, squamous epithelium frequently grows over metaplastic glands in patients who
are treated with PPIs, perhaps as a consequence of the extensive esophageal biopsy
procedures used during endoscopic surveillance.
Whether or not the risk of buried metaplasia after ablation is exaggerated, it is clear that
cancer can develop in some patients who are treated with endoscopic eradication therapy. A
recent systematic review and meta-analysis found 43 reported cases of esophageal cancer
that occurred in patients who had undergone endoscopic ablation for Barrett's esophagus
without dysplasia (4 of 1457 cases), low-grade dysplasia (2 of 239 cases), or high-grade
dysplasia (37 of 611 cases).263 Those data were used to calculate weighted-average
incidence rates for cancer development after endoscopic ablation therapy as follows: 1.63
cancers per 1000 patient-years (95% CI, 0.07–3.34) for Barrett's esophagus without
dysplasia, 1.58 cancers per 1000 patient-years (95% CI, 0.66–3.84) for low-grade dysplasia,
and 16.76 cancers per 1000 patient-years (95% CI, 10.6–22.9) for high-grade dysplasia.
In summary, large, prospective, randomized trials have established that endoscopic ablation
therapy with PDT and RFA is superior to treatment with PPIs alone for preventing the
progression from high-grade dysplasia to cancer in Barrett's esophagus. Compared with PDT
with porfimer sodium, RFA appears to have a better safety profile and is easier to
administer. Large, nonrandomized, and uncontrolled cohort studies have shown excellent
long-term survival rates for carefully selected patients with high-grade dysplasia and early
cancer who are treated with EMR. Recurrent or metachronous cancers occur frequently in
those patients, however, especially if the residual Barrett's epithelium is not ablated.
Nevertheless, the recurrent cancers usually are amenable to further endoscopic eradication
therapy.
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It remains unclear whether the excellent results for endoscopic eradication therapy reported
by the few expert centers that have studied those techniques can be reproduced in the
community. The durability of the eradication therapy, the frequency and importance of
buried metaplasia, and the long-term efficacy of ablation therapy for cancer prevention
remain unsettled issues. With those caveats, we conclude that endoscopic eradication
therapy is a reasonable therapeutic option for patients with high-grade dysplasia in Barrett's
esophagus, especially in those for whom advanced age or comorbid illness renders
esophagectomy inordinately hazardous (see the following text). If endoscopic eradication
therapy is to be used, we recommend that any visible abnormalities should be removed by
EMR, which provides invaluable staging information as well as therapy, followed by the
ablation of all remaining Barrett's metaplasia.
Is Esophagectomy Still a Reasonable Option for Patients Who Have High-Grade Dysplasia
in Barrett's Esophagus?
For decades, esophagectomy had been the traditional treatment recommended for patients
with high-grade dysplasia in Barrett's esophagus.86 For those patients, esophagectomy
definitively eliminated all of the esophagus lined by Barrett's epithelium (dysplastic and
nondysplastic) and, unlike modern endoscopic therapies, allowed for the removal of
associated lymph nodes that could harbor metastases. Unfortunately, esophagectomy also
could be associated with substantial rates of mortality and long-term morbidity. In some
series of patients with esophageal cancer treated by esophagectomy, the operative mortality
rate exceeded 20%. Indeed, the burgeoning interest in endoscopic eradication therapy for
dysplasia in Barrett's esophagus has been fueled largely by the perception that
esophagectomy has unacceptably high rates of mortality and long-term morbidity (Table 3).
A number of studies have shown that mortality rates for esophagectomy are inversely related
to the frequency with which the operation is performed at any given medical center.264 In a
study of data from the Dutch National Medical Registry, for example, the mortality rates for
esophagectomy were 12.1%, 7.5%, and 4.9% at centers performing 1 to 10, 11 to 20, and
>50 esophagectomies per year, respectively.265 Other reports have described esophagectomy
mortality rates for high- and low-volume medical centers of 2.5% and 15.4%,266 2.7% and
16%,267 3.4% and 17.3%,268 4.8% and 16%,269 and 8.4% and 20.3 %,270 respectively.
Therefore, one way to reduce the mortality from esophagectomy is to have the operation
performed by an experienced surgeon who practices in a center that has a high volume for
esophagectomy.
Estimated mortality rates for esophagectomy have been based largely on series of patients
who had the operation performed for the treatment of symptomatic esophageal cancers.86
Such patients are often elderly and debilitated by the dysphagia and anorexia that often
accompany such advanced esophageal tumors. In addition to patients with adenocarcinoma
in Barrett's esophagus, furthermore, those series often have included patients with squamous
cell carcinoma of the esophagus, many of whom have had severe comorbid illnesses caused
by the cigarette smoking and alcoholism associated with that tumor. One would anticipate
substantially lower mortality rates for esophagectomy performed to treat dysplasia or early
cancer in younger and otherwise healthy patients with Barrett's esophagus. In support of this
notion, reports of a number of modern small series have described excellent survival rates
when esophagectomy is performed primarily or exclusively for such patients (Table
4).271–300 Most of those studies have found no operative mortality, and none have described
a mortality rate that exceeds 3.3%.
Esophagectomy can cause distressing symptoms such as dysphagia, early satiety, loss of
appetite, and fatigue, which can seriously impair quality of life. Most studies that have
addressed specifically the issue of quality of life after esophagectomy have included
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primarily patients who had the operation because of advanced esophageal cancer, and the
results of such studies may not be applicable to patients who undergo esophagectomy for
asymptomatic neoplasia in Barrett's esophagus. Virtually all studies that have assessed
quality of life in the immediate postoperative period have found that quality of life declines
significantly immediately after esophagectomy.301 However, most,302–305 but not all,306,307
long-term studies also have found that the quality of life returns to or even exceeds baseline
levels by 3 months to 2 years after esophagectomy. Other studies that have assessed long-
term function, years after esophagectomy, have found that the patients' quality of life scores
are similar to those of control subjects in the general population.308–310
Two studies have focused on quality of life primarily in patients who underwent
esophagectomy for high-grade dysplasia or early cancer in Barrett's esophagus. One study of
34 such patients found that SF-36 results obtained at a mean follow-up of 46 months after
esophagectomy were equal to or better than those of a healthy control population.279 The
other study included 36 patients who had esophagectomy for high-grade dysplasia or
intramucosal carcinoma and who were followed up for a mean duration of 4.9 years. Similar
to the previous study, SF-36 scores for the patients were similar to those of age- and sex-
matched control subjects.278
Although esophagectomy generally is considered the most definitive of the therapeutic
options for patients with dysplasia in Barrett's esophagus, new columnar metaplasia (cardia
type and intestinal type) develops frequently in the esophageal remnant in patients who have
had esophagectomy with esophagogastrostomy, presumably as a consequence of the reflux
esophagitis that often accompanies this procedure.311–315 Conceivably, those patients might
be at risk for developing adenocarcinoma in the neo-metaplastic epithelium, and there are
rare case reports of such an occurrence.316–318 Nevertheless, the risk of carcinogenesis in
the Barrett's epithelium that develops after esophagectomy appears to be very small.
In summary, esophagectomy for high-grade dysplasia in Barrett's esophagus definitively
removes all of the esophagus at increased risk for malignancy (unlike limited EMR and
endoscopic ablation), provides a specimen that can be examined for evidence of invasion
(unlike endoscopic ablation), and obviates the concern that local lymph nodes might contain
metastases (unlike EMR and ablation). When performed in otherwise healthy individuals
with dysplasia in Barrett's esophagus, the mortality rate for the operation is substantially less
than 5%, and the long-term quality of life after esophagectomy is good in most cases. Thus,
the option of esophagectomy still warrants serious consideration, especially for younger and
otherwise fit patients who have high-grade dysplasia in Barrett's esophagus.
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Appendix
Search Algorithms Used in Systematic Reviews
What Is the Definition of Barrett's Esophagus? What Landmark Identifies
the Gastroesophageal Junction? What Epithelial Type Is Required for the
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Diagnosis of Barrett's Esophagus? Should Endoscopists Measure the
Extent of Barrett's Metaplasia?
To identify relevant papers on the definition of Barrett's esophagus and the interrelated
topics of identification of the gastroesophageal junction, histologic evaluation of esophageal
biopsy samples for a determination of epithelial type, and measurement of the extent of
Barrett's metaplasia, the text words “Barrett esophagus” were combined with the medical
subject heading (MeSH) search terms “definition,” “epithelium,” “gastroesophageal
junction,” “esophagogastric junction,” “diagnosis” (limited to title and abstract only),
“extent,” or “length.” Relevant papers were selected from a yield of 1236.
What Is the Risk of Esophageal Cancer for the General Population of
Patients With Barrett's Esophagus? What Is the Natural History of
Dysplasia in Barrett's Esophagus?
To identify relevant papers on the progression and regression of patients with Barrett's
esophagus with regard to dysplasia and esophageal adenocarcinoma, the search keywords
“Barrett esophagus” or Barrett metaplasia” or “Barrett's mucosa” or “Barrett's epithelium”
were combined with MeSH search terms “dysplasia” or “esophageal cancer” or “esophageal
neoplasm.” Relevant papers were selected from a yield of 305,425 references.
Does Barrett's Esophagus Affect Life Expectancy? How Does a Diagnosis
of Barrett's Esophagus Affect Quality of Life?
To identify relevant papers on the impact of a diagnosis of Barrett's esophagus on life
expectancy, the search keywords “Barrett esophagus” or Barrett's oesophagus” or “Barrett
metaplasia” or “Barrett's mucosa” or “Barrett's epithelium” were combined with search
keywords “life expectancy” or “mortality.” Relevant papers were selected from a yield of
525 papers. Bibliographies of relevant articles were reviewed for additional pertinent
manuscripts not encapsulated by the search. Reported data were retrospective cohort and
case-control data reporting mortality. To define relevant papers on quality of life, we used
the MeSH search terms “Barrett esophagus” and “quality of life” as well as the terms
“Barrett's esophagus,” “Barrett esophagus,” “Barrett's,” and “intestinal metaplasia”
combined with the terms “quality of life,” “QoL,” “HRQoL,” “SF-36,” “QOLRAD,”
“GIQLI,” “burden,” and “economic impact.” We also searched the MeSH search term
“GERD” with the MeSH search term “quality of life” in addition to the term “Barrett's
esophagus.” Appropriate manuscripts were selected from 102 papers. We subsequently
assessed the bibliographies of all identified relevant articles to identify data missed on the
initial literature search. Reported studies were cohort studies, case series, or clinical trials.
Who Is at Risk for Barrett's Esophagus? Who Should Be Screened for
Barrett's Esophagus?
To identify relevant papers on risk factors for Barrett's esophagus, the search keywords
“Barrett esophagus” or Barrett's oesophagus” or “Barrett metaplasia” or “Barrett's mucosa”
or “Barrett's epithelium” were combined with search keywords “risk factor” and
“prevalence.” Relevant papers were selected from 1932 citations. Regarding who should be
screened for Barrett's esophagus, the search keywords “Barrett esophagus” or Barrett's
oesophagus” or “Barrett metaplasia” or “Barrett's mucosa” or “Barrett's epithelium” were
combined with the MeSH search term “screening.” From 4597 citations, case-control
studies, cohort data, and cross-sectional studies were retrieved. We subsequently assessed
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the bibliographies of all identified relevant articles to identify data missed on the initial
literature search.
Does Endoscopic Surveillance Improve Survival for Patients With Barrett's
Esophagus?
To identify relevant papers on the role of endoscopic surveillance on mortality from
esophageal adenocarcinoma, the keywords “Barrett esophagus” or “esophageal” and
“adenocarcinoma” were combined with MeSH search terms “mass screening” or “early
detection of cancer” or “surveillance” or “endoscopy.” Relevant papers were selected from a
yield of 3250 references.
Can Biomarkers Be Used to Confirm the Histologic Diagnosis of
Dysplasia? Can Biomarkers Be Used Instead of Dysplasia for Risk
Stratification in Barrett's Esophagus?
To identify relevant papers on the role of biomarkers for confirming a diagnosis of dysplasia
and for risk stratification in Barrett's esophagus, the text words “Barrett esophagus” were
combined with the MeSH search terms “biomarker,” “molecular,” “mutation,” “deletion,”
“heterozygosity,” “gene,” or “genetic.” Relevant papers were selected from a yield of 608.
Should Chromoendoscopy or “Electronic Chromoendoscopy” Be Used to
Enhance the Detection of Metaplasia and Dysplasia in Barrett's
Esophagus?
To identify relevant papers on the role of chromoendoscopy and related techniques for the
yield of Barrett's esophagus and dysplasia, the following keywords and MeSH search terms
were used: “Barrett esophagus” and “chromoendoscopy” or “electronic chromoendoscopy”
or “narrow band imaging” or “FICE” or “NBI.” Relevant papers were selected from a yield
of 109 references.
Should Advanced Endoscopic Imaging Techniques Such as
Autofluorescence Imaging, Confocal Laser Endomicroscopy, Diffuse
Reflectance and Light Scattering Spectroscopy, and Optical Coherence
Tomography Be Used to Enhance the Detection of Metaplasia and
Dysplasia in Barrett's Esophagus?
To identify relevant papers on the role of spectroscopy, autofluorescence, confocal
endomicroscopy, and related techniques for the yield of Barrett's esophagus and dysplasia,
the following keywords and MeSH search terms were used: “Barrett esophagus” and
(“adenocarcinoma” or “dysplasia” or “metaplasia”) and (“advanced imaging” or “optical
coherence” or “spectroscopy” or “reflectance” or “endomicroscopy” or “endoscopic
imaging” or “imaging”). Relevant papers were selected from a yield of 1551 references.
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Should Proton Pump Inhibitors Be Used for Chemoprevention in Barrett's
Esophagus? Should Nonsteroidal Anti-inflammatory Drugs Be Used for
Chemoprevention in Barrett's Esophagus?
To identify relevant papers on the role of proton pump inhibitors and nonsteroidal anti-
inflammatory drugs for chemoprevention in Barrett's esophagus, the text words “Barrett
esophagus” were combined with the MeSH search terms “proton pump inhibitor,” “PPI,”
“nonsteroidal anti-inflammatory drugs,” or “NSAID.” Relevant papers were selected from a
yield of 391.
Should Antireflux Surgery Be Advised to Prevent Cancer in Barrett's
Esophagus?
To identify relevant papers on the role of antireflux surgery for cancer prevention in
Barrett's esophagus, the text words “Barrett esophagus” were combined with the MeSH
search terms “fundoplication,” “antireflux surgery,” or “cancer risk.” Relevant papers were
selected from a yield of 1214.
What Is the Role for EMR in Barrett's Esophagus? Should Endoscopic
Eradication Be Used to Treat Patients Who Have Barrett's Esophagus
Without Dysplasia? Should Endoscopic Eradication Be Used to Treat
Patients Who Have Barrett's Esophagus With Low-Grade Dysplasia?
Should Endoscopic Eradication Be Used to Treat Patients Who Have
Barrett's Esophagus With High-Grade Dysplasia or Intramucosal
Carcinoma?
To identify relevant papers on the role of endoscopic therapies on the treatment of Barrett's
esophagus, dysplasia, and esophageal adenocarcinoma, the following keywords and MeSH
search terms were used: “Barrett esophagus” and (“adenocarcinoma” or “dysplasia”) and
(“endoscopic mucosal resection” OR “ablation” OR “endoscop*” OR “therap*”). Relevant
papers were selected from a yield of 382 references.
Is Esophagectomy Still a Reasonable Option for Patients Who Have High-
Grade Dysplasia in Barrett's Esophagus?
To identify relevant papers on the role of esophagectomy for patients with high-grade
dysplasia in Barrett's esophagus, the text words “Barrett esophagus” were combined with the
MeSH search terms “esophagectomy,” “resection,” or “dysplasia.” Relevant papers were
selected from a yield of 1516.
Abbreviations used in this paper
AFI autofluorescence imaging
AGAI American Gastroenterological Association Institute
APC argon plasma coagulation
CI confidence interval
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CPQMC Clinical Practice and Quality Management Committee
EMR endoscopic mucosal resection
EUS endoscopic ultrasonography
GEJ gastroesophageal junction
GERD gastroesophageal reflux disease
GRADE Grading of Recommendations Assessment, Development and Evaluation
LOH loss of heterozygosity
PEC multi-polar electrocoagulation
NBI narrow band imaging
PDT photodynamic therapy
PPI proton pump inhibitor
QOLRAD Quality of Life in Reflux and Dyspepsia
RFA radiofrequency ablation
RR relative risk
SEER Surveillance, Epidemiology and End Results
SF-36 36-Item Short Form Health Survey
TR technical review
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